Analysis Group

Managing Principal Min Yang Coauthors Article on Evolving HEOR Requirements

Mon, 31 Aug 2026 17:45:57 Z

Health economics and outcomes research (HEOR) has long drawn credibility from its methodological strength and the scientific value associated with it. However, in this contemporary era, expectations for HEOR professionals are becoming more demanding and are increasingly requiring skillsets that expand beyond technical grounding. Effective researchers are those with strong technical abilities along with strategic minds, cross-audience communication abilities, and policy awareness as they are asked to translate technical outcomes into easily understood value messages to inform leadership and, potentially, influence policy decisions.

To examine this evolution, Analysis Group Managing Principal Min Yang joined a Partnership Group forum during ISPOR 2026, “Building Your HEOR Skillset: Core Skills for Advancing Your Career.” Participants, including professionals from Otsuka, OPEN Health, Eli Lilly, and Novartis, discussed how the role of individual HEOR contributors has shifted and the resulting industry demand for soft skills.

In summary of this and two other sessions, forum participants coauthored a Value and Outcomes Spotlight article. In their discussion, the authors note that decision makers respond better to clearly communicated key takeaways based on HEOR evidence, rather than recitations of methodological details. The article also touches on tightening international policies raising the evidentiary bar for HEOR studies, along with recommendations for embedding such research strategies earlier in product development.

Read the article

Analysis Group Consultants Map Biologic Therapy Initiation and Adherence in Severe Asthma, Examining the Role of Social Determinants of Health

Thu, 27 Aug 2026 19:50:44 Z

Biologic therapies can play an important role in managing severe asthma, but patients may encounter barriers to initiating treatment, have difficulty taking their medications consistently, or discontinue therapies over time. Social determinants of health (SDOH) – including education, poverty, housing conditions, internet access, unemployment, and racial or ethnic minority status – may shape patients’ access to and continued use of these treatments. Because adherence to biologic therapies is associated with fewer exacerbations, understanding how SDOH relate to therapy initiation and adherence may help inform efforts to improve patient outcomes.

To examine this, Analysis Group Principal François Laliberté, Vice President Guillaume Germain, and Associate Patrick Gravelle – together with Rohit K. Katial from National Jewish Health and the University of Colorado, Diego J. Maselli from the University of Texas Health at San Antonio, and Justin Kwiatek and Arijita Deb from GSK – conducted a study analyzing how patient characteristics and social determinants of health may be associated with biologic therapy initiation and adherence among patients with severe asthma, as well as how adherence relates to asthma exacerbations. The researchers conducted a large US health care claims analysis incorporating individual- and area-level SDOH measures and used geospatial mapping techniques to visualize geographic variation in biologic initiation and adherence across the country. The researchers also assessed adherence and its association with asthma exacerbation rates among patients who initiated a biologic.

In an article on their findings published in the Journal of Asthma and Allergy, the authors note disparities in both biologic initiation and adherence among patients with different SDOH and observe that dosing schedules appeared to be an important factor in adherence. Their findings suggest that adherence may be higher for biologics with longer dosing intervals, indicating that treatments requiring less frequent administration may offer an important therapeutic option. The authors suggest that considering the socioeconomic and geographic contexts in which patients live could inform future efforts to improve access to treatment and support continuity of care for this population.

Read the article

Analysis Group Researchers Co-investigate Optimal Metrics for Improving Clinical Outcomes Among Patients with Prostate Cancer

Wed, 26 Aug 2026 19:50:54 Z

Among patients with metastatic castration-sensitive prostate cancer (mCSPC), undetectable levels (less than 0.2 ng/mL) of absolute prostate-specific antigen (PSA) within nine months of initiating treatment have been associated with improved survival outcomes, as compared to a percentage of PSA decline. Despite this, 85 percent of physicians surveyed used a percentage of PSA decline as the key metric of patient response to treatment, indicating an educational gap between reliance on recommended metrics and real-world practices. Further information about the connection between absolute PSA levels and clinical outcomes may help health care providers understand whether patients with mCSPC could be candidates for more or less intensive treatment regimens.

To provide a perspective on optimal PSA metrics for bedside decisions, Analysis Group Managing Principal Hongbo Yang, Vice President Wei Gao, and Senior Analysts Jingyi Chen and Grace Chen collaborated with investigators from Cedars-Sinai Medical Center, Astellas Pharma, and Pfizer on a retrospective analysis of Veterans Health Administration (VHA) patient data. In an article on their findings, the researchers observed improved clinical outcomes among patients with mCSPC who had undetectable absolute PSA levels, regardless of the percentage of their PSA decline. They also found that patients initiating intensified treatments were more likely to achieve those low absolute PSA levels. The authors conclude that an absolute PSA low point of less than 0.2 ng/mL – as opposed to a percentage of PSA decline – is the optimal measure for identifying patients with mCSPC who are likely to have improved survival outcomes and delayed disease progression.

The study, “How low do you need to go? Association between various prostate-specific antigen response measures and clinical outcomes in metastatic castration-sensitive prostate cancer in the Veterans Health Administration data,” was featured in the American Society of Clinical Oncology’s (ASCO’s) Cancer in the News (paywall) and published in Cancer, the Interdisciplinary International Journal of the American Cancer Society.

Read the article

Second Circuit Upholds Finding of Anticompetitive Conduct Brought by Analysis Group Client Cumulus Media Against Nielsen

Wed, 26 Aug 2026 17:44:44 Z

Analysis Group was retained on behalf of the radio broadcast company Cumulus Media, the plaintiff in an antitrust lawsuit against The Nielsen Company, a market research firm. Cumulus Media, which operates both a national audio network and local radio stations, alleged that Nielsen engaged in an illegal tying scheme when it adopted a policy that conditioned subscribers’ access to its national radio ratings data on the purchase of ratings data for local markets in which they operate. Cumulus Media stated that this arrangement would force it to purchase ratings data for markets for which it had no need of data in order to gain access to the national data it needed to sell ads for its national network. It sought an injunction against Nielsen preventing it from enforcing the arrangement.

An Analysis Group team led by Managing Principal Emily Cotton, Principal Mark Lewis, and Vice President Federico Mantovanelli supported Harold Furchtgott-Roth, who filed an expert report and testified at deposition. A media and telecommunications industry expert, Dr. Furchtgott-Roth opined that Nielsen exercised market power both in the national radio ratings market and in each of the local radio ratings markets for which it gathered data. He further opined that Nielsen’s arrangement was an illegal tie because it leveraged its market power in national market to entrench its market power in the market for local ratings data.

A judge in the US District Court for the Southern District of New York granted Cumulus Media’s motion for a preliminary injunction, barring Nielsen’s arrangement from taking effect. Citing Dr. Furchtgott-Roth’s submissions throughout the opinion, the district court held that Cumulus Media was likely to succeed on its claims of antitrust injury because Nielsen’s policy “flatly prohibits the sale of the complete nationwide product unless purchased with all local ratings data.” The injunction was subsequently upheld by a panel of the US Court of Appeals for the Second Circuit.

Analysis Group Client Obtains Favorable Economic Domestic Industry Finding in USITC Investigation

Tue, 25 Aug 2026 21:09:32 Z

Analysis Group was retained by Mayer Brown on behalf of Maxell, a Japanese technology company, in a Section 337 investigation before the US International Trade Commission (ITC). Maxell alleged that Samsung Electronics imported and sold smartphones and tablets that infringed several Maxell patents. Maxell sought to establish the economic prong of Section 337’s domestic industry requirement based on US investments by Motorola Mobility, a licensee of the asserted patents, in nearly two dozen Motorola smartphones identified as domestic industry products and released between 2022 and 2025.

An Analysis Group team led by Vice Presidents Andrea Hugill and Dave Maber supported Managing Principal John Jarosz, who filed an expert report and provided economic analysis and expert testimony at both deposition and the evidentiary hearing. Mr. Jarosz analyzed Motorola’s US investments in plant and equipment and its employment of labor and capital associated with domestic industry products. His work included allocating investments and employment to the domestic industry products practicing each asserted patent and providing qualitative and quantitative context regarding the significance of those investments.

Relying in significant part on Mr. Jarosz’s analysis and testimony, the presiding administrative law judge found that Maxell had satisfied the economic prong of the domestic industry requirement, concluding that the relevant US activities reflected significant investments in plant and equipment and significant employment of labor and capital related to the domestic industry products. The ALJ found one exception for the ‘103 patent under subsection (B), for which Maxell had not shown any investments; the patent had been issued only shortly before the end of the period analyzed.

Analysis Group Authors Examine Efficiencies in the European Commission’s Draft Merger Guidelines

Tue, 25 Aug 2026 17:21:57 Z

The treatment of efficiencies has become one of the central questions raised by the European Commission’s draft guidelines for assessing mergers under the EU Merger Regulation (the Draft Guidelines). The public consultation on the Draft Guidelines closed at the end of June 2026. In an article for the Kluwer Competition Law Blog, Analysis Group Managing Principal Joshua White and Associate Claire Paoli teamed up with Jay Modrall of Norton Rose Fulbright to examine the extent to which the Draft Guidelines deliver on the European Commission’s promise to better account for the potential benefits of deals in merger assessments.

The authors welcomed the substantial shift in the European Commission’s approach. Notably, the Draft Guidelines outline a “theory of benefit” that is placed, in principle, on an equal footing with theories of harm within a single integrated analysis rather than being treated as a late-stage “defence.” The authors also commended the expanded treatment of dynamic efficiencies relating to investment and innovation.

However, if benefits and harms are to be weighed on an equal footing, the authors suggest three areas for improvement. The first relates to relatively simple changes to improve consistency and conformity, such as taking a more balanced approach to evidence and better integrating sustainability and resilience benefits. The second involves eliminating unnecessary asymmetries between the European Commission’s assessments of harms and benefits. In particular, the authors highlight asymmetries in the types of evidence required and in the emphasis placed on the quantification of harms and benefits.

The final area for improvement concerns two requirements in the Draft Guidelines that the authors note do not derive from EU law and limit the consideration of potential benefits. The authors question the feasibility of the new requirement that efficiencies relate not only to the merging parties’ activities but also to “competition as a whole,” “including rivals’ activities” (paras. 301, 315). They also challenge the Draft Guidelines’ broad exclusion of out-of-market and collective benefits based on an unconvincing analogy to the Horizontal Cooperation Guidelines and case law under Article 101 TFEU. Analysis Group authors previously responded to the European Commission’s Consultation on the Draft Merger Guidelines.

Read the article

Analysis Group Authors Examine Efficiencies in the European Commission’s Draft Merger Guidelines

Tue, 25 Aug 2026 17:06:05 Z

Lexology Index Recognizes Thirteen Analysis Group Experts and Consultants in Competition Economics

Mon, 24 Aug 2026 16:00:32 Z

Thirteen Analysis Group experts and consultants were recognized in Lexology Index’s 2026 Competition – Economists ranking.

One expert was named a Global Elite Thought Leader:

Managing Principal Antoine Chapsal (France)

Four consultants were named Thought Leaders:

Principal Emmanuel Frot (France)
CEO Pierre Y. Cremieux (USA)
Chairman Martha S. Samuelson (USA)
Senior Advisor Keith R. Ugone (USA)

Three consultants were named Highly Recommended:

Senior Advisor Jeffrey A. Cohen (USA)
Managing Principal Dov Rothman (USA)
Co-founder Bruce E. Stangle (USA)

Five experts and consultants were named Recommended:

Independent Consultant Paul E. Godek (USA)
Vice President Cyril Hariton (Belgium)
Competition Expert Pierre Régibeau (Belgium)
Managing Principal Joshua White (England)
Managing Principal Rebecca Kirk Fair (USA)

View the Lexology Index Competition report

Lexology Index Recognizes Thirteen Analysis Group Experts and Consultants in Competition Economics

Fri, 21 Aug 2026 19:03:12 Z

Thirteen Analysis Group experts and consultants were recognized in Lexology Index’s 2026 Competition – Economists ranking.

One expert was named a Global Elite Thought Leader:

Managing Principal Antoine Chapsal (France)

Four consultants were named Thought Leaders:

Principal Emmanuel Frot (France)
CEO Pierre Y. Cremieux (USA)
Chairman Martha S. Samuelson (USA)
Senior Advisor Keith R. Ugone (USA)

Three consultants were named Highly Recommended:

Senior Advisor Jeffrey A. Cohen (USA)
Managing Principal Dov Rothman (USA)
Co-founder Bruce E. Stangle (USA)

Five experts and consultants were named Recommended:

Independent Consultant Paul E. Godek (USA)
Vice President Cyril Hariton (Belgium)
Competition Expert Pierre Régibeau (Belgium)
Managing Principal Joshua White (England)
Managing Principal Rebecca Kirk Fair (USA)

View the Lexology Index Competition report

42nd International Society for Pharmacoepidemiology (ISPE) Annual Meeting

Fri, 21 Aug 2026 15:27:57 Z

Analysis Group, a global leader in drug safety epidemiology and regulatory RWE, will co-moderate one podium presentation session and present five research posters at the 42nd International Society for Pharmacoepidemiology (ISPE) Annual Meeting.

On Monday, August 31, from 3:30 to 5:00 p.m. CEST, in the Gold Room, Vice President Marianne Cunnington will co-moderate podium session 2C, “How Do Exposed Pregnancies End?”

On Tuesday, September 1, from 11:30 a.m. to 1:00 p.m. CEST, during poster session B in the Exhibition South Hall, researchers from Analysis Group – including Managing Principals Maral DerSarkissian, Mei Sheng Duh, and Mihran Yenikomshian, and Vice Presidents Marianne Cunnington, Lynn Huynh, and Enrico Zanardo – will present the following posters:

B-011: Clinical Characteristics and Treatment Patterns in Cisplatin-Eligible versus Cisplatin-Ineligible Muscle-Invasive Bladder Cancer Patients with Intent for Resection: A Multi-Country Retrospective Chart Review in Europe
B-054: Comparison of Patient Reported Outcomes in Interstitial Lung Disease with and without Pulmonary Hypertension: Interim Results from the PHINDER Study
B-063: Real World Continuity of Care for Medicare Patients with Plaque Psoriasis Treated with Tildrakizumab and Other Treatment Classes
B-249: More than Just Fit-for-Use Data: a Structured Framework to Support Real World Study Decision Making

On Wednesday, September 2, from 12:15 to 1:15 p.m. CEST, in the Exhibit Hall, Managing Principal Maral DerSarkissian will present a rare disease spotlight poster:

SLC-033: Clinical Characteristics Associated with Pulmonary Hypertension among Patients with Interstitial Lung Disease: Interim Results from the PHINDER Study

Further details on the podium presentation session and posters are available in our 2026 ISPE Presentation Guide. Analysis Group is a proud gold sponsor of this meeting.

Navigating Merger Enforcement in Cross-Border Deals

Thu, 20 Aug 2026 14:52:18 Z

As merger review guidance shifts in Europe, the UK, and the US, economic experts with former enforcement experience are well-positioned to help counsel navigate resulting complexities. Three such experts from Analysis Group will participate in a ThoughtLeaders4 (TL4) Competition webinar on challenges associated with understanding mergers across borders.

Vice President Markus von Wartburg will moderate a discussion between Managing Principal Aditi Mehta, Competition Expert Pierre Régibeau, Paul Gilbert (Cleary Gottlieb), and John Fedele (Baker McKenzie). The panelists will cover practical considerations for those encountering cross-border deals, including evolving EU and UK horizontal merger guidelines, transatlantic alignment and fragmentation, and how to present credible efficiencies arguments before regulators.

53rd Annual Conference on International Antitrust Law and Policy

Wed, 19 Aug 2026 20:09:44 Z

Analysis Group Managing Principal Aditi Mehta will join the panel Trends in Merger Enforcement: Is International Convergence Still a Goal? on Friday, September 18, 2026, from 2:50 to 4:05 p.m., at Fordham Competition Law Institute’s 53rd Annual Conference on International Antitrust Law and Policy. The panel will be moderated by Ori Schwartz (OECD). Other panelists will include Elizabeth Avery (Gilbert + Tobin), Rafique Bachour (Skadden, Arps, Slate, Meagher & Flom), and Guillaume Loriot (European Commission).

Analysis Group is pleased to be a supporting sponsor of the event.

Navigating Merger Enforcement in Cross-Border Deals

Tue, 18 Aug 2026 17:13:33 Z

Register

Managing Principal Joshua White and Vice President Philipp Tillmann Present at Informa CompLaw: Summer School

Tue, 18 Aug 2026 13:48:59 Z

Competition experts from Analysis Group joined the faculty of the 28th edition of Informa CompLaw: Summer School, a comprehensive week-long introductory course on EU and UK competition law and economics. Managing Principal Joshua White (based in London and Brussels) and Vice President Philipp Tillmann (based in Paris and Brussels) were among the senior regulators, lawyers, academics, and economic consultants delivering tailored sessions for legal professionals seeking to deepen their understanding of competition law. Held at Cambridge University’s Downing College, the program brought together participants from competition authorities, law firms, and corporations around the world for a week of learning and networking.

Mr. White joined Bristows Partner Sophie Lawrance in discussing the interaction between intellectual property (IP) rights and EU competition law, with particular focus on Articles 101 and 102 of the Treaty on the Functioning of the European Union (TFEU). They considered whether, and why, IP rights may require distinct legal and economic treatment, before exploring how Article 101 applies to IP-related agreements. The discussion touched on the Technology Transfer Block Exemption Regulation, issues arising under Article 102 (including settlement agreements, patent abuse, and obligations to license), as well as practical enforcement questions and the role of economic analysis.

Dr. Tillmann presented alongside Andrew Morrison, Of Counsel at Wilson Sonsini, on competition law issues arising in labor markets, including no-poach agreements and wage-fixing arrangements. He examined when such conduct may raise anticompetitive concerns, when it may generate procompetitive efficiencies, and how those effects can be assessed. Dr. Tillmann also discussed lessons from enforcement activity in the United States.

Managing Principal Joshua White and Vice President Philipp Tillmann Present at Informa CompLaw: Summer School

Tue, 18 Aug 2026 13:46:55 Z

42nd International Society for Pharmacoepidemiology (ISPE) Annual Meeting

Thu, 13 Aug 2026 18:50:24 Z

On Monday, August 31, from 3:30 to 5:00 p.m. CEST, in the Gold Room, Vice President Marianne Cunnington will co-moderate podium session 2C, “How Do Exposed Pregnancies End?”

B-011: Clinical Characteristics and Treatment Patterns in Cisplatin-Eligible versus Cisplatin-Ineligible Muscle-Invasive Bladder Cancer Patients with Intent for Resection: A Multi-Country Retrospective Chart Review in Europe
B-054: Comparison of Patient Reported Outcomes in Interstitial Lung Disease with and without Pulmonary Hypertension: Interim Results from the PHINDER Study
B-063: Real World Continuity of Care for Medicare Patients with Plaque Psoriasis Treated with Tildrakizumab and Other Treatment Classes
B-249: More than Just Fit-for-Use Data: a Structured Framework to Support Real World Study Decision Making

On Wednesday, September 2, from 12:15 to 1:15 p.m. CEST, in the Exhibit Hall, Managing Principal Maral DerSarkissian will present a rare disease spotlight poster:

SLC-033: Clinical Characteristics Associated with Pulmonary Hypertension among Patients with Interstitial Lung Disease: Interim Results from the PHINDER Study

Further details on the podium presentation session and posters are available in our 2026 ISPE Presentation Guide. Analysis Group is a proud gold sponsor of this meeting.

Analysis Group Affiliate Lee Tiedrich Charts a Path Toward Closing the AI Evaluation Gap

Wed, 12 Aug 2026 16:23:53 Z

Current AI evaluation methods often fail to reflect real-world performance. The disparity between the power of new AI systems and our ability to measure their effectiveness and safety is known as the AI evaluation gap. Closing the gap could boost trust, security, adoption, and policy clarity while lowering costs and barriers to competition. In an OECD.AI blog post, affiliate Lee Tiedrich proposes a five-step roadmap toward bridging this divide, including balancing standardization with customization, testing AI applications throughout their life cycles, and tailoring evaluations of those tools to different actors across the AI value chain.

“Lee gets at something the field has been circling for a while: Evaluating AI tools is an ongoing discipline that has to evolve alongside the technology itself.” – Jimmy Royer

The full article is available on OECD.AI's blog, The AI Wonk: A five-step roadmap to closing the AI evaluation gap

Ms. Tiedrich has also been active elsewhere in the AI policy conversation, appearing on NPR's All Things Considered to discuss AI regulation and presenting at Ai4 2026, North America’s largest AI conference.

Analysis Group Study Evaluates Real-World Outcomes of Earlier-Line Multiple Myeloma CAR-T Therapy

Thu, 06 Aug 2026 14:50:16 Z

Patients with relapsed or refractory multiple myeloma (RRMM) – a blood cancer that has returned or stopped responding to treatment – often require multiple rounds of therapy as their disease progresses. Clinical trials have shown that ciltacabtagene autoleucel (cilta-cel), a CAR-T cell therapy, can help patients with RRMM remain free from disease progression without requiring subsequent treatment. Following expanded regulatory approval, cilta-cel is now available earlier in the treatment journey for those patients. As its use expands, real-world evidence (RWE) is needed to determine whether the outcomes observed in clinical trials are replicated in routine clinical practice.

To understand how well trial outcomes translate to patient care, Analysis Group Vice President Bruno Emond and Manager Jessica Maitland collaborated with investigators from Memorial Sloan Kettering Cancer Center, Johnson & Johnson, Legend Biotech USA, and UT Southwestern Medical Center on a study of patients with RRMM treated with cilta-cel after one to three prior lines of therapy. The study used medical records and physician notes from the largest US real-world cohort to date evaluating minimal residual disease (MRD) negativity (i.e., that no cancer cells were detectable after treatment) among patients with RRMM who received cilta-cel as an early-line therapy. The researchers assessed how those patients responded to treatment, whether any cancer remained detectable after treatment, and whether their disease worsened or required additional therapy during follow-up.

In an article on their findings, the researchers report that – among patients evaluated for MRD – 97.2% had no detectable remaining cancer after treatment with cilta-cel. Together with a high overall response rate (98.0%) and observed proportion of patients who remained free from disease progression and did not require further therapy during follow-up (95.8%), the study's findings provide early RWE of rapid and effective disease control among patients with RRMM who were treated with early-line cilta-cel, reflecting outcomes previously observed in clinical trials. Longer follow-up and repeated MRD measurements may provide further insights into MRD as a prognostic marker for response durability and survival outcomes, helping to contextualize the potential role of cilta-cel in achieving a functional cure for patients with RRMM.

The study, “IMMPACT-MM: Insights into Multiple Myeloma Patient Outcomes Following Ciltacabtagene Autoleucel Treatment in Earlier Lines of Therapy in the Real World,” was published in Oncology and Therapy.

Read the article

In Ethylene Cartel Follow-On Litigation, Amsterdam Court Dismisses Claims Against Analysis Group Client

Wed, 05 Aug 2026 19:20:45 Z

Analysis Group was retained by White & Case and Houthoff on behalf of defendant Vestolit, a polymer chemicals business unit of Orbia, in connection with follow-on litigation related to the European Commission’s 2020 finding that Vestolit participated in an infringement related to ethylene procurement along with other major chemical companies. In two separate antitrust matters, ethylene sellers Shell Chemicals Europe and Repsol brought damages claims against Vestolit, alleging that the defendants’ coordination on the ethylene monthly contract price (MCP) caused the MCP – and the resulting price of ethylene – to be set too low.

An Analysis Group team led by Principal Chris Feige, Vice President Philipp Tillmann, and Managers Arjun Dasgupta and Elena Nota provided a damages assessment in both matters. Mr. Feige submitted expert reports and testified at a hearing in March 2026 in the District Court of Amsterdam; his testimony focused on an assessment of the plausibility of the claimants’ damages analysis and the economic impact of the alleged infringement.

The District Court of Amsterdam dismissed both claimants’ damages claims against Vestolit. Adopting Mr. Feige’s critiques of the claimants’ damages theories, the court found the asserted effect of the cartel’s communication on the MCP was not plausible.

In Ethylene Cartel Follow-On Litigation, Amsterdam Court Dismisses Claims Against Analysis Group Client

Wed, 05 Aug 2026 19:13:22 Z

Market Responses to Voluntary Most-Favored Nation Deals Examined by Analysis Group Consultants

Mon, 03 Aug 2026 17:22:08 Z

Under the Trump administration’s most-favored nation (MFN) drug pricing initiative, a stated objective is for US patients to pay no more for a drug than patients in other wealthy countries. MFN policies have generally been viewed as potential threats to pharmaceutical company revenues and their incentives to invest in costly research and development activities. In practice, however, the voluntary agreements announced to date have focused primarily on Medicaid and TrumpRx and have also included some tariff-risk protections tied to commitments to invest in US-based manufacturing.

To assess how investors interpreted these developments, Analysis Group academic affiliate Amitabh Chandra, Managing Principal Noam Y. Kirson, Manager John Dooley, and Analyst Alice Ge conducted an event study. The researchers examined stock-price data for the 16 public companies among the 17 manufacturers that had announced MFN agreements. They analyzed market reactions around several milestones, including the administration's April 2, 2025 “Liberation Day” announcement, the July 31, 2025 letters that the administration sent to pharmaceutical manufacturers regarding MFN pricing, Pfizer’s first formal agreement announcement, and subsequent agreement announcements.

In Health Affairs Scholar, the authors report that investors did not interpret the MFN agreements announced to date as materially value-destructive. The strongest market response followed the first MFN deal announced by Pfizer, which generated largely positive reactions across most of the pharmaceutical companies analyzed, likely because the deal was seen as less harmful than initially feared. The authors suggest that the agreements’ relatively narrow focus on Medicaid and TrumpRx, together with the resolution of some regulatory and tariff uncertainty, may help explain market responses. They further caution that future expansion of MFN may lead to different market reactions.

Read the article

Managing Principal Joshua White and Principal Jessica Resch on Expert Hot Tubbing in International Arbitration

Thu, 30 Jul 2026 14:21:29 Z

Analysis Group and Latham & Watkins recently hosted an event in London for the Chartered Institute of Arbitrators’ (CIArb) Young Members Group on the use of expert witness conferencing in international arbitration, often referred to as “hot tubbing.”

Analysis Group Managing Principal Joshua White and Principal Jessica Resch acted as opposing experts in a hypothetical damages case study. Latham & Watkins Associate Shreya Ramesh took the role of tribunal chair, guiding the experts through the key issues and testing the areas of agreement and disagreement. The case study showed that conferencing is not just a procedural concept, but an approach that can shape how expert evidence is presented, tested, and understood. The discussion was co-moderated by Analysis Group Manager Arjun Dasgupta and Latham & Watkins Associate Evangeline Tsui.

Hot Tubbing Can Take Several Formats

Expert witness conferencing is not a single fixed procedure. The demonstration compared two different approaches: In one, the tribunal led, putting questions to both experts and inviting them to respond to each other’s views in real time, keeping the discussion tightly focused on the issues the tribunal considered most important. In the other, the experts led with the technical points they considered central and engaged more directly with each other’s analysis. This gave the tribunal a different perspective on where the experts themselves saw the points of disagreement.

In practice, many cases may benefit from a hybrid approach: conferencing with a clear structure and agenda, tribunal control where needed, and room for experts to engage directly as issues emerge.

Where Witness Conferencing Can Work Well

At its best, expert witness conferencing can be a highly effective way to clarify technical evidence. Rather than hearing from experts sequentially, sometimes days or even weeks apart, the tribunal hears them address the same question side by side, making it easier to see where the experts genuinely disagree.

This can be particularly useful in disputes involving quantum or valuation questions, where the tribunal often needs to understand not only each expert’s conclusion, but also the reasoning behind it. A well-run conference can surface important practical questions such as which assumptions are driving the difference, which inputs matter most, and whether the experts are using different methodologies or applying the same one differently.

Conferencing can also help identify which disagreements have the biggest impact on the outcome. That is valuable in complex disputes where expert reports may contain numerous differences, but only a few affect the result.

Points for Counsel to Consider

Despite its advantages, expert conferencing is not a cure-all. Counsel and tribunals should think carefully before adopting it.

A key risk is lack of structure. Without a clear agenda, a free-flowing discussion can become unfocused or dominated by the more outspoken expert, who may not have the strongest analysis and evidence.

Preparation is also critical. Expert conferencing generally works best where the areas of agreement and disagreement have already been narrowed, often through joint expert reports or agreed-upon agendas. An overly broad set of questions makes the discussion inefficient; too rigid an agenda loses the benefit of experts engaging directly as issues become clearer during the discussion.

Counsel should also be alive to witness dynamics; some experts are naturally more comfortable in an interactive format than others. An expert who is measured, cautious, or less forceful should not automatically be seen as less persuasive. It is important to ensure the tribunal hears clear, balanced, and focused answers from both sides – the substance rather than the personalities.

A Tool that Rewards Thoughtful Planning

The practical takeaway for counsel is simple: Propose expert witness conferencing where it will help the tribunal better understand the evidence. Carefully plan the issues to be discussed, the order in which issues will be addressed, who leads the questioning, how experts may respond to one another, and where counsel examination fits into the process.

Designed thoughtfully, expert conferencing can be one of the most useful parts of an arbitration hearing. It can expose weak assumptions, clarify real disagreements, and help tribunals make better-informed decisions.

Managing Principal Joshua White and Principal Jessica Resch on Expert Hot Tubbing in International Arbitration

Thu, 30 Jul 2026 14:02:42 Z

Hot Tubbing Can Take Several Formats

In practice, many cases may benefit from a hybrid approach: conferencing with a clear structure and agenda, tribunal control where needed, and room for experts to engage directly as issues emerge.

Where Witness Conferencing Can Work Well

Points for Counsel to Consider

Despite its advantages, expert conferencing is not a cure-all. Counsel and tribunals should think carefully before adopting it.

A Tool that Rewards Thoughtful Planning

Analysis Group Responds to the Israel Competition Authority's Consultation on Draft Merger Guidelines

Fri, 24 Jul 2026 14:28:13 Z

Competition economists from Analysis Group have responded to the Israel Competition Authority’s (ICA) call for input on its Draft Merger Guidelines (Draft Guidelines), published for public consultation on April 26, 2026. Managing Principal Samuel Weglein, Manager Zsolt Udvari, and Associate Gleb Gertsman welcomed the ICA’s expanded treatment of efficiencies, market power, and non-horizontal mergers, relative to its 2011 guidelines.

Running through the authors’ submission was a call for greater transparency regarding the analytical tools and economic evidence, both quantitative and qualitative, that the ICA applies in testing theories of harm – an approach, the authors noted, that has increasingly been reflected in international practice. The submission identifies a number of areas in which additional clarity would support a more transparent, predictable, and rigorous merger review process in Israel.

A more balanced view of startup acquisitions and conglomerate mergers

The authors recommended a more balanced assessment of both types of transactions, recognizing not only the potential competition concerns they can raise, such as “killer acquisitions” or foreclosure, but also the procompetitive benefits they can generate through innovation, commercialization, and the integration of complementary assets. Among other suggestions, they proposed that the ICA more explicitly acknowledge the potential procompetitive benefits of acquisitions involving innovative startups. As one possible mechanism, the ICA could consider adopting an “innovation shield” (similar to a concept in the Draft EU Merger Guidelines) to provide greater predictability for acquisitions of small, innovative companies.

Strengthening the treatment of efficiencies

The authors also urged the ICA to strengthen its treatment of merger-specific efficiencies and benefits by encouraging early engagement on efficiencies, recognizing dynamic and innovation-related efficiencies alongside short-term cost savings, and drawing on recent international developments such as the EU’s “theory of benefit” framework.

Practical refinements to market power analysis

On market power, the authors called for clearer guidance on non-price competition, the role of potential entry and expansion by rivals, the interpretation of the revised structural presumption thresholds, and a less rigid treatment of imports for a small, open economy like Israel’s.

Read Analysis Group's full response

Analysis Group Responds to the Israel Competition Authority's Consultation on Draft Merger Guidelines

Fri, 24 Jul 2026 14:20:39 Z

A more balanced view of startup acquisitions and conglomerate mergers

Strengthening the treatment of efficiencies

Practical refinements to market power analysis

Read Analysis Group's full response

Women Leaders in Life Sciences Law

Wed, 22 Jul 2026 18:06:16 Z

Analysis Group Vice President Erica VanSant will join a panel on Most Favored Nation (MFN) drug pricing at the 13th Annual Summit for Women Leaders in Life Sciences Law. The session, MFN Drug Pricing and the Future of Global Pharmaceutical Markets: Understanding the Implications for Pricing, Access, and Innovation, will examine the evolving MFN policy landscape and the ways legal and business leaders are evaluating its potential ripple effects across global markets. The discussion will address implications for pricing strategies, market entry and launch sequencing, and the US innovation pipeline.

Analysis Group is pleased to be an associate sponsor of the event.

Robust Economics in an Evolving Transatlantic Competition Enforcement Landscape

Tue, 21 Jul 2026 13:35:14 Z

Political change, regulatory reform, and geopolitical uncertainty are major preoccupations for companies and their counsel navigating international mergers. These pressures were the focus of a recent GCR Live Europe event in Brussels, where competition experts, practitioners, and other stakeholders addressed the current and future landscapes of antitrust enforcement in the EU and US.

Two experienced Analysis Group competition practitioners, Managing Principal Aditi Mehta and Competition Expert Pierre Régibeau, participated in the event. Drawing on their significant experience as economists in leadership positions in US and EU agencies, Drs. Mehta and Régibeau addressed how lawyers can interpret enforcement developments without losing sight of the economic fundamentals that continue to drive outcomes.

Across the discussions, a common theme emerged: Despite changes in competition policy, robust economic analysis remains fundamental in competition law enforcement. Political priorities and institutional developments may affect timing, process, and stakeholder engagement, but they do not change the need for careful evidence, disciplined economic reasoning, and close collaboration between lawyers and economists.

Demystifying Antitrust Enforcement in the US

Dr. Mehta, a former economics director of enforcement at the US Department of Justice (DOJ) Antitrust Division, offered a grounded perspective on the extent to which merger review in the US has and has not changed in recent years. Outside the few high-profile transactions that may have attracted political attention, Dr. Mehta emphasized that the majority of deals filed before the US agencies continue to be reviewed in a familiar way. She noted that economists at the DOJ and Federal Trade Commission (FTC) have continued to focus on the same economic fundamentals – that is, whether the evidence clearly indicates that a deal gives rise to competition concerns – and that the path to merger clearance in the US still depends on developing a strong economic and factual record. Political advisors may become more relevant in certain matters, particularly those involving sensitive sectors or public-facing issues, but they do not replace the role of economics.

Dr. Mehta’s panel also discussed the growing importance of state attorneys general in US merger review. States are increasingly active and better resourced, with some expanding their antitrust teams, hiring economists, using outside counsel, and collaborating with one another. Several states have also introduced filing requirements that can bring more transactions to the attention of state enforcers. As a result, parties may need to account for new, state-level requirements when filing, rather than simply focusing on those usually considered by the DOJ or FTC. For some transactions – particularly those affecting local markets, labor, health care, or industries of state-level importance – US merger planning may increasingly resemble a multi-jurisdictional exercise.

The Road Ahead for EU Antitrust Enforcement

Dr. Régibeau, former Chief Competition Economist at the European Commission, joined a panel on what comes next for EU antitrust enforcement. He addressed the frequently heard view that, by giving a greater role to structural presumptions – the idea that certain market structures inherently harm competition – the European Commission’s Draft Guidelines on exclusionary abuse of dominance might narrow the role of economists. He noted that such presumptions are at the very core of economic analysis: Economics rarely gives us certainty, presumptions are the norm. Although economic analysis may not fit neatly within a policy approach that draws a red line between “by-object” infringements and effect-based analysis, Dr. Régibeau suggested that the use of presumptions can, in fact, help focus economic analysis on the most important aspects of the case. He raised the example of pure bundling – offering a suite of products without the option of purchasing them individually. The clear conclusion of the literature is that, without clear efficiencies, such arrangements are likely to be anticompetitive. If that presumption were to be accepted, regulators could then focus on any specifics of a case that might reverse the presumption instead of spending time reexamining the bundling debate. This could allow the work of economists to be more focused and effective.

A shift toward reliance on presumptions may also change the way economists and lawyers work together. The focus of economists’ work may move away from more general, abstract analyses and toward more targeted ones designed around the questions that matter most for a specific case. In that sense, the role of the economist would not be diminished; it would become more integrated with legal strategy.

The discussion also considered vertical restraints, enforcement of interim measures, and the relationship between competition policy and industrial policy. On the topic of vertical restraints, Dr. Régibeau highlighted that part of the EU’s framework for vertical restraints enforcement – namely, the protection of online sales – is now seen by some as outdated. Although protecting online sales was a focus 10 years ago, that concern may have become obsolete as a policy priority, given that online sales are a mature part of many markets rather than an emerging channel. He argued that enforcement of vertical restraints should focus on issues that are relevant for the internal market today. Regarding interim measures, Dr. Régibeau suggested that, as invasive as they may seem, internal measures can benefit the parties under investigation by allowing the Commission to avoid rushed decisions that may be unnecessarily detrimental to the parties. In his closing remarks, Dr. Régibeau emphasized that industrial policy and competition policy are complementary, not exclusive alternatives to each other.

Robust Economics in an Evolving Transatlantic Competition Enforcement Landscape

Tue, 21 Jul 2026 13:33:05 Z

Demystifying Antitrust Enforcement in the US

The Road Ahead for EU Antitrust Enforcement

Managing Principal Andrea Okie Reviews ABA Panel on Regulation and Competition

Fri, 17 Jul 2026 15:50:09 Z

How do competition policy and regulation coexist in the modern US economy? That was the dominant theme of a panel titled “Regulation Rollback and Market Competition” at this year’s American Bar Association (ABA) Antitrust Law Section Spring Meeting. The panel was moderated by Karina Lubell of the Brunswick Group (formerly of the US Department of Justice (DOJ) Antitrust Division) and featured panelists Alexis Gilman of Alston & Bird, Elinor Hoffmann of the Office of the New York State Attorney General, Diana Moss of the Progressive Policy Institute, and Sarah Scheinman of Sidley Austin. Analysis Group Managing Principal Andrea Okie summarized the panel in an article published on the Antitrust Law Section website.

Much of the discussion traced how competition considerations are folded – unevenly – into regulatory review at both the federal and state levels, and contrasted the Biden administration's broad, enforcement-driven approach to dominant firms with the second Trump administration's deregulatory, executive order–driven push to lower barriers to entry. Panelists agreed that despite these differing philosophies, procompetitive reform faces persistent structural headwinds, and that practitioners advocating for such reform need to work within the “public interest” standards that govern much of agency rulemaking, tying arguments to prevailing policy priorities and grounding them in empirical evidence.

Ms. Okie's recap drew out several broad takeaways: that fragmented, inconsistent federal and state regulatory frameworks create both uncertainty and openings for advocacy; that competition policy tends to track broader political currents but also converges on shared goals such as market access and transparency even across differing administrations; and that structural barriers – capture, entrenchment, and limited enforcement resources – complicate reform regardless of which party is pushing it. The panelists advised keeping an eye on emerging business models and technologies, such as algorithmic pricing, and on state legislatures and agencies as areas to watch for where competition policy may be headed.

Read the article

Vice President Anne Catherine Faye Assesses FTC Financial Deception Enforcement and Rulemaking in New ABA Article

Thu, 16 Jul 2026 15:57:12 Z

Financial deception is an increasingly important enforcement priority for the Federal Trade Commission (FTC). Since 2025, the agency has initiated enforcement actions targeting earnings claims, business opportunities, multilevel marketing (MLM) programs, AI-enabled money-making schemes, and gig-economy compensation representations. Many of these actions have resulted in substantial monetary relief, despite the US Supreme Court’s 2021 decision in AMG Capital Management LLC v. FTC, which limited the FTC’s ability to seek certain financial remedies.

In an article for the American Bar Association (ABA) Antitrust Law Section, Analysis Group Vice President Anne Catherine Faye examines how the FTC has adapted its consumer protection enforcement strategy in the wake of AMG Capital. She describes how the agency has shifted its approach, relying more heavily on alternative statutory authorities, enforcement partnerships, and rulemaking initiatives.

In the article, Ms. Faye reviews recent enforcement actions involving allegedly deceptive earnings representations and financial opportunity claims, including matters related to investment training programs, MLM ventures, AI-related business opportunities, and gig-economy platforms. She also observes that, in dealing with AI-related claims, the FTC is applying traditional deception principles rather than developing a particular framework for a new technology. The analysis highlights how the FTC continues to pursue financial deception matters across a range of markets while adapting to the post–AMG Capital legal landscape.

Read the article

Amid Rising Private Credit Defaults, Analysis Group Authors Explore Loan Covenant Mix as Signal of Borrower Risk

Wed, 15 Jul 2026 14:12:04 Z

The US Federal Reserve and market participants have expressed concern over the increased rate of defaults in the private credit market, now estimated at approximately $3 trillion. In an environment of rising default risk, accurate information about borrower quality is crucial for lenders. In an article for Law360, Analysis Group authors explore an underappreciated source of information about borrower risk: the mix of financial covenants that borrowers agree to comply with in their loan contracts.

In their article, Vice President Carlo Gallimberti, Manager David Tsui, and academic affiliate Christopher Armstrong explain that the rise in stressed debt in private credit markets coincides with a trend in which loans containing relatively few covenants – or “cov-lite” loans – have become the dominant form of lending. The authors reference their prior research showing that even when loans contain few financial covenants, the combination of accounting measures they rely on can still convey meaningful information about borrower risk. For example, borrowers who intend to pursue riskier strategies are more likely to steer the negotiation toward loan covenants tied to balance sheet measures such as liquidity as opposed to those tied to profits because negative shocks are less likely to trip the former. In contrast, businesses anticipating less risk are more likely to agree to loan covenants tied to profitability, especially when paired with cheaper loan spreads. The authors emphasize that what matters is not the total number of covenants but the mix of covenants that borrowers select. The article concludes by discussing implications of this research for both lenders and borrower counsel in the deal room.

Analysis Group Responds to European Commission’s Consultation on Draft Merger Guidelines

Fri, 10 Jul 2026 14:07:28 Z

Competition economists from Analysis Group’s European offices welcomed the opportunity to respond to the European Commission’s call for input on its Draft Merger Guidelines, published for public consultation on April 30, 2026. Noting that the Draft Guidelines were “a substantial step forward in the Commission’s approach to merger assessment,” the authors – Competition Expert Pierre Régibeau; Managing Principals Antoine Chapsal, Marc Van Audenrode, and Joshua White; Principal Emmanuel Frot; and Vice President Cyril Hariton – offered recommendations that would provide greater clarity and specificity in their practical implementation. These observations were intended to support the Commission’s efforts to develop a more comprehensive, balanced, and modern framework for merger assessment in Europe, while identifying specific areas in which revisions or additional clarity would promote a more transparent and predictable merger review process.

A new “theory of benefit”

The authors highlighted that the introduction of a theory of benefit showed a shift in the Commission’s treatment of efficiencies from a “defense” against potential anticompetitive harm, toward a more balanced consideration of potential benefits and harms in a consolidated assessment. Commending the Commission’s increased focus on efficiencies, the authors nonetheless identified several questions related to the scope and definition of efficiencies and the Commission’s balancing exercise and applicable evidentiary standards.

The authors’ practical recommendations for additional guidance in implementing the new theory of benefit include:

The role of geographic considerations in assessing resilience-related benefits (e.g., “domestic versus foreign” dimensions);
Appropriate time horizons for assessing efficiencies in sectors with long innovation and investment cycles;
A consistent analytical framework for balancing harms and benefits, drawing on methodologies already used in the Commission’s wider policymaking tools; and
Greater clarity on how out-of-market and collective benefits should be considered where they are valued by consumers affected by the merger.

Competitive assessment

The Draft Guidelines also provide updated guidance on the Commission’s approach to the assessment of market power and potential anticompetitive effects. The authors welcomed the updates and consolidation of elements of the Commission’s approach in cases over the past 20 years. The practical refinements offered in the authors’ report pertain to the assessment of dynamic competition, innovation, ecosystem markets, and emerging theories of harm, aimed at improving predictability, transparency, and legal certainty. In particular, the authors encouraged the use of modern quantitative tools to support merger assessment, with clearer guidance on when different techniques are appropriate and how they should inform the Commission’s evaluation of competitive effects.

Read Analysis Group’s full response

Analysis Group Responds to European Commission’s Consultation on Draft Merger Guidelines

Fri, 10 Jul 2026 13:38:04 Z

A new “theory of benefit”

The authors’ practical recommendations for additional guidance in implementing the new theory of benefit include:

The role of geographic considerations in assessing resilience-related benefits (e.g., “domestic versus foreign” dimensions);
Appropriate time horizons for assessing efficiencies in sectors with long innovation and investment cycles;
A consistent analytical framework for balancing harms and benefits, drawing on methodologies already used in the Commission’s wider policymaking tools; and
Greater clarity on how out-of-market and collective benefits should be considered where they are valued by consumers affected by the merger.

Competitive assessment

Read Analysis Group’s full response

Analysis Group Experts to Guest Edit Obesity-Themed Issue of PharmacoEconomics

Thu, 09 Jul 2026 14:44:09 Z

The treatment landscape for obesity is rapidly changing. While GLP-1 medications have generated significant public interest, important questions have been raised about their long-term effectiveness, affordability, and accessibility. Simultaneously, digital health tools, behavioral modification techniques, and surgical options have attracted attention as complements or alternatives to pharmacologic intervention.

A forthcoming issue of PharmacoEconomics on obesity will be guest edited by Managing Principal Noam Kirson and affiliate Professor John Cawley. The journal invites health care economists, outcomes researchers, payers, providers, and decision makers to submit original research, reviews, opinion pieces, or policy analyses for publication.

Topics of interest include:

Trends in obesity prevalence
Obesity-associated disease burden
Medication reimbursement, pricing, and access
Long-term disease and economic modeling
Real-world evidence (RWE) on treatment patterns and outcomes
Equity and ethical considerations

Abstracts are due to the publisher no later than September 30, 2026.

View the full call for papers

DP&E Town Hall: European RPM Enforcement

Wed, 08 Jul 2026 14:01:39 Z

Vice President Olga Kozlova Guglielmi will moderate an American Bar Association Antitrust Law Section Diverse Perspectives & Engagement Town Hall on European resale price maintenance (RPM) enforcement. The webinar will explore key takeaways from recent RPM cases across European industries, from luxury fashion to consumer electronics. Panelists will include Christiane Dahlbender (Mars Inc), Marie-Laure Allain (Ecole Polytechnique), Maud Boukhris (Willkie Farr & Gallagher LLP), and Morag Elwis (Freshfields US LLP).

DP&E Town Hall: European RPM Enforcement

Wed, 08 Jul 2026 13:58:37 Z

EU Merger Guidelines – New Wine and New Bottle?

Wed, 01 Jul 2026 12:47:55 Z

Analysis Group Manager Cecilia Caliandro will participate in an ABA Antitrust Law Section webinar discussing the European Commission’s latest draft merger guidelines, published on April 30, 2026. Daniele Calisti, head of unit for Merger Policy and Case Support in the European Commission’s Directorate-General for Competition, will join the webinar to discuss the significant changes in the draft that reflect 20 years of experience since the current guidelines were adopted. The panel will include moderator James R. Modrall (Norton Rose Fulbright) and speaker Alden Abbott (George Mason University).

EU Merger Guidelines – New Wine and New Bottle?

Wed, 01 Jul 2026 12:41:29 Z

ICC Tribunal Adopts Analysis Group Damages Analysis in Beauty Industry Breach-of-Contract Dispute

Tue, 30 Jun 2026 20:52:28 Z

Analysis Group was retained on behalf of Insil and Sunna Kim, the former owners of the skincare and cosmetics company The Crème Shop and the respondents in an arbitration matter involving an alleged contract breach. South Korean consumer goods company LG Household & Health Care (LG) purchased a majority ownership stake of The Crème Shop from Insil and Sunna Kim in a Stock Purchase Agreement (SPA). LG subsequently filed International Chamber of Commerce (ICC) arbitration against the two former owners: Among other claims, LG alleged that the former owners’ involvement in other beauty-related business activities violated the non-compete provision of the SPA.

An Analysis Group team led by Vice President Kimberly Attia supported Vice President Thomas McGahee, who prepared a damages rebuttal report and testified at the hearing. Dr. McGahee challenged LG’s damages theory and presented an analysis of lost profits based on the sales of the at-issue competitors.

Although the tribunal found in favor of LG on liability, it relied on Dr. McGahee’s rebuttal testimony in its rejection of LG’s damages analysis, calling LG’s methodology “unconvincing.” The final award adopted Dr. McGahee’s lost profits analysis, which represented 3% of the damages asserted by LG.

Global Merger Control Conference

Thu, 25 Jun 2026 15:57:11 Z

Managing Principal Antoine Chapsal will moderate the closing panel of the Global Merger Control Conference in Paris, organized by Concurrences. Under this year’s theme, “Agencies and General Counsel: What’s on their radar?”, the program will bring together competition authorities, legal practitioners, leading economists and industry representatives to discuss how merger policy in the EU and the US is adapting to today’s geopolitical context and how those changes are affecting merger review. Alongside François-Charles Laprévote (Cleary Gottleib) and William E. Kovacic (GWU Law School), Dr. Chapsal will draw together the day’s key themes, bringing an economic perspective to how competition analysis is evolving and what these developments mean for companies navigating increasingly complex regulatory environments.

Analysis Group is pleased to sponsor this event.

Global Merger Control Conference

Wed, 24 Jun 2026 18:26:03 Z

Analysis Group is pleased to sponsor this event.

Analysis Group Hosts 2026 Health Care and Life Sciences Litigation Practice Day

Wed, 17 Jun 2026 16:30:30 Z

Analysis Group consultants gathered in Philadelphia for a day of presentations and discussions about current issues and emerging trends in health care and life sciences (HCLS) litigation. Event participants covered key topics, including:

Takeaways from recent court rulings and litigation trends in HCLS disputes, including those involving:
- Antitrust;
- False Claims Act (FCA);
- Food and nutrition;
- Product liability, drug safety, and pharmaceutical mass torts;
- Payer-provider;
- Privacy and data security;
- Intellectual property; and
- Securities matters
How expert analysis of Medicare Advantage can be useful in questions of causation and damages in a large variety of HCLS cases, including, but not limited to, antitrust, FCA, and breach of contract matters.
How AI can be useful in HCLS litigation but also the source of disputes
An analysis of trends in Daubert challenges of HCLS experts over the last ten years.

ICC Tribunal Adopts Analysis Group Damages Analysis in Beauty Industry Breach-of-Contract Dispute

Tue, 16 Jun 2026 18:33:10 Z

Analysis Group Experts Support Bondholders in Puerto Rico Electric Power Authority Rate Review

Mon, 15 Jun 2026 16:00:21 Z

Analysis Group worked with the Puerto Rico Electric Power Authority’s (PREPA’s) legacy bondholders in PREPA’s rate review before the utility’s regulator, the Puerto Rico Energy Bureau (PREB). PREPA serves the entire island and its 3.2 million residents. The utility filed for bankruptcy in 2017 to restructure approximately $9 billion in debt – the largest municipal utility bankruptcy in US history. The rate review represented the first reset of PREPA’s electricity base rates since 2017, and PREPA submitted a multi-billion-dollar operational and capital budget for the fiscal years 2026-2028.

An Analysis Group team led by Managing Principal Brian Gorin and Vice Presidents Charles Wu and Lindsay Greenbaum supported industry experts Patrick Hogan and Anthony Hurley, who assessed PREPA’s proposed expenses, the executability of a proposed capital budget, and the use of federal funding. The team also supported Analysis Group Senior Advisor Susan Tierney, who opined on rate design and mechanisms for potential future payment of legacy debt. The three experts each submitted written testimony and testified at the rate review hearings.

In its final rate order, PREB extensively cited the work of Analysis Group’s experts in its decision to reduce expenses borne by ratepayers and reclassify expenses to federal funding pathways. PREB also instituted a placeholder legacy debt rider, a measure recommended by Dr. Tierney, as it would “allow [PREPA] to begin collecting funds to make legacy debt payments in a more expeditious manner” once the bankruptcy was resolved.

Testimony by Analysis Group Affiliate Glenn Hubbard Supports Exclusion of Opposing Expert’s Damages Model in Event-Driven Securities Litigation Involving Mining Company

Thu, 11 Jun 2026 17:47:55 Z

Analysis Group was retained by Gibson Dunn on behalf of Vale S.A., one of the largest mining companies in the world, the defendant in a long-running Rule 10b-5 securities fraud class action. The class plaintiffs, purchasers of Vale stock and bonds, alleged that the company and certain executives made a series of misstatements about the company’s risk-management practices and the safety of its operations. When a dam at one of Vale’s mines subsequently collapsed, the prices of the company’s securities fell. The plaintiffs sought damages related to the decline in the value of Vale’s securities after the incident.

An Analysis Group team led by Managing Principal Mark Egland, Principal Kevin Gold, Vice President Ahmer Nabi, and Managers Anastasia Bogdanova and Thomas Zimmerfaust supported academic affiliate Glenn Hubbard, who filed an expert report and testified at deposition and at a Daubert motion hearing. In his rebuttal to plaintiffs’ expert’s damages analysis, Professor Hubbard explained that an appropriate damages analysis should isolate the impact of the alleged fraud, including assessing the difference between investors’ assessment of the probability of an adverse event occurring given the alleged misrepresentations, and the ‘true’ probability of the event occurring. In particular, Professor Hubbard critiqued the plaintiffs’ expert’s contention that 100% of the drops in the securities’ prices after the dam collapse were due to the allegedly fraudulent statements, rendering the expert’s damages model unreliable from an economic perspective.

The US District Court for the Eastern District of New York excluded the plaintiffs’ expert’s damages calculation. In its opinion, the court agreed with the defendants’ “principal criticism of Dr. Feinstein’s damages model” and found the plaintiffs’ expert’s damages model unreliable. Specifically, the court agreed with Professor Hubbard regarding the appropriate damages framework involving the materialization of an understated risk, noting that “the appropriate measure of inflation is the difference between the perceived and actual risk of a dam collapse,” and, relatedly, that the plaintiffs’ expert’s model “fails to disaggregate the investment losses caused by Vale’s alleged misrepresentations – i.e., the ostensible understatement of the risk – from the losses caused by the actual dam collapse.”

Managing Principal Lisa Pinheiro Featured in Wall Street Journal Article on Committee Working to Improve Safeguards for Prediction Market Kalshi

Thu, 11 Jun 2026 15:53:19 Z

Analysis Group Managing Principal Lisa Pinheiro is serving on the Independent Market Integrity Committee engaged by the prediction market Kalshi to help strengthen its market integrity safeguards. The committee, which was formed as part of an expansion of Kalshi’s surveillance and enforcement framework, is tasked with providing independent scrutiny of Kalshi activity in order to guard against market manipulation, insider trading, and attempted fraud.

According to an article in The Wall Street Journal, the committee has recommended tighter security measures to address the risk that users may trade in certain event markets based on material nonpublic information. Kalshi plans to require users participating in some sensitive markets, including those related to company performance and national security, to disclose their employers, with the goal of improving surveillance, supporting investigations of suspicious activity, and deterring potential misuse.

The Independent Market Integrity Committee brings together expertise in financial crime enforcement, forensic analytics, and financial economics. Its members include Brian Nelson, former US Treasury Under Secretary for Terrorism and Financial Intelligence and a partner at Cooley LLP; Daniel Taylor, director of the Wharton Forensic Analytics Lab and a professor at The Wharton School of the University of Pennsylvania; and Ms. Pinheiro, an expert in quantitative financial economics and market manipulation analytics.

Resale Price Maintenance Primer: 2026

Thu, 11 Jun 2026 15:35:35 Z

Vice President Kristof Zetenyi will speak at the American Bar Association Antitrust Law Section webinar, Resale Price Maintenance Primer: 2026. The program will cover legal considerations, economic theory, and practical tips related to resale price maintenance.

Dr. Zetenyi will join speakers Courtney Ballard (Rome LLP), Luis Blanquez (Bona Law PC), and Melissa Maxman (Cohen & Gresser LLP). The webinar is co-sponsored by the Distribution and Franchising Committee and the Economics Committee.

Managing Principal Lisa Pinheiro Featured in Wall Street Journal Article on Committee Working to Improve Safeguards for Prediction Market Kalshi

Wed, 10 Jun 2026 16:50:56 Z

Read more in The Wall Street Journal

Affiliate Catherine Tucker Examines the AI Stack and Competition and Market Frictions at Analysis Group Events

Tue, 09 Jun 2026 17:28:21 Z

Analysis Group affiliate Catherine Tucker shared how AI is altering the competition landscape at private dinner events in New York City and Washington, DC, hosted by the firm. Professor Tucker is an industrial organization economist and the Sloan Distinguished Professor of Management at the MIT Sloan School of Management. She heads the NBER Initiative on Digital Economics and AI. The dinner programs were organized by Managing Principals Kris Comeaux, Rebecca Kirk Fair, Andrea Okie, and Aaron Yeater.

In her remarks, Professor Tucker described the layers of the AI stack and the competitive dynamics in each. She emphasized that we should not be distracted by the current profitability of different layers of the AI stack, and that economists should still consider whether barriers to entry exist in the form of network effects, switching costs, or unique data inputs for any layer in the stack. She described her current work detailing the lack of network effects in the applications layer and industry innovations that are reducing switching costs.

Professor Tucker analogized the current competitive environment in the AI stack to prior waves of technological innovation, including internet service providers, search, and e-commerce. She also engaged in a question-and-answer session with the audience.

Vice President Cyril Hariton Assists Cycling Equipment Manufacturer SRAM in Antitrust Dispute Against International Cycling Union

Mon, 08 Jun 2026 20:17:40 Z

Analysis Group Vice President Cyril Hariton was retained by Norton Rose Fulbright on behalf of SRAM, a manufacturer of cycling transmission systems, in a competition complaint filed against Union Cycliste Internationale (UCI) in connection with UCI’s maximum gearing technical standard. The matter concerned UCI’s Maximum Gear Ratio Test Protocol, which would have limited the maximum gear ratio allowed in certain professional road cycling events. SRAM challenged the protocol before the Belgian Competition Authority (BCA), arguing that the rulemaking process was not transparent, objective, or non-discriminatory, and that the protocol would disproportionately affect SRAM and professional teams using SRAM drivetrain systems.

Dr. Hariton supported SRAM before the BCA, assessing the competition economics issues and available safety-related statistical data. He also demonstrated that there was no convincing quantitative evidence capable of supporting UCI’s standard.

The BCA imposed interim measures suspending implementation of the protocol. Subsequently, the Brussels Court of Appeal (Markets Court) dismissed UCI’s appeal in full and affirmed the BCA’s decision. The Markets Court confirmed that the BCA had validly concluded, on a prima facie basis, that the protocol raised competition concerns due to shortcomings in transparency, objectivity, and non-discrimination. The court also found that UCI had not justified why the protocol was necessary and proportionate to advance rider safety, and that the BCA had properly assessed the risk of serious, immediate, and difficult-to-repair harm to SRAM and teams using SRAM transmission systems.

Vice President Cyril Hariton Assists Cycling Equipment Manufacturer SRAM in Antitrust Dispute Against International Cycling Union

Mon, 08 Jun 2026 20:15:54 Z

Analysis Group Announces Three Senior-Level Promotions

Fri, 05 Jun 2026 17:19:44 Z

Analysis Group is pleased to announce the promotion of Rene Befurt and Joshua White to managing principal and Carletta Wong to principal.

“These promotions recognize the accomplishments of Rene, Josh, and Carletta, who have demonstrated leadership, deep expertise, and a commitment to delivering high-quality client work across our practices, including marketing, surveys, and behavioral economics; competition and pharmaceutical litigation; and complex finance matters,” said Pierre Cremieux, CEO of Analysis Group. “Their promotions further strengthen our client offerings through both the breadth of their expertise and the depth of their contributions, including mentoring our deep bench of professionals, helping expand our affiliate network, and reinforcing our culture of outstanding work and consistent platform development.”

New Managing Principals

Rene Befurt specializes in applying marketing research and survey methodologies to litigation and strategic business issues. He has extensive experience designing and implementing survey experiments, choice modeling, and conjoint analyses to assess consumer behavior. Dr. Befurt has served as an expert witness in matters involving patent infringement, trademark disputes, false advertising, product liability, and consumer disclosures, and has testified at deposition and trial. He has consulted to clients, including the US Department of Justice, the Federal Trade Commission, and leading multinational corporations across industries such as automotive manufacturing, technology, and consumer goods. His work includes designing survey instruments, analyzing complex survey data, and creating tools that use market simulations to help clients understand consumer preferences and market forces. He has also evaluated brand perception and consumer decision making to support expert testimony in litigation.

Joshua White is a consulting and testifying economist who specializes in applying microeconomics and econometrics to complex litigation and merger-related questions, primarily in matters involving the health care, financial services, and technology industries. He has supported clients in various jurisdictions, assessing overcharge, upstream and downstream pass-on, and volume effects. He has testified in the UK Upper Tribunal (Lands Chamber), the UK Competition Appeal Tribunal, and the Amsterdam District Court. Mr. White has supported companies in high profile mergers including Veolia/Suez, LVMH/Tiffany, Sika/MBCC, and Eutelsat/OneWeb. He has also provided evidence to the UK’s Competition and Markets Authority (CMA) and the European Commission in mergers and cartel and abuse of dominance investigations. Mr. White has provided support to European financial and competition regulators in coordinated conduct investigations. He has supported scientific and technical testifying experts on competition and intellectual property issues in matters related to pharmaceutical products and FRAND licensing questions. He also regularly works with pharmaceutical clients on competition issues associated with market access, pricing, and denigration. Mr. White has worked in a number of jurisdictions around the world and has published in multiple journals, including the Journal of European Competition Law & Practice, the Competition Law Journal, and the Journal of Antitrust Enforcement. He regularly speaks at international competition law and policy conferences.

New Principal

Carletta Wong has experience applying expertise in economics and financial analysis to support experts in a variety of litigation and international arbitration matters, including those involving corporate transactions and governance, finance, accounting, antitrust, pharmaceutical reverse payments, commercially reasonable efforts, intellectual property and trade secrets, and government investigations of pharmaceutical clients. Her case work has spanned a broad range of industries, including health care, entertainment and media, telecommunications, finance, software and technology, real estate, and manufacturing. In several complex commercial disputes in the Delaware Chancery Court, Ms. Wong has led the support for teams of experts addressing valuation and damages, solvency, corporate governance, platform economics, and media and technology issues. She has extensive experience in cases involving M&A, including matters with controlling shareholder dynamics and material adverse change allegations. In addition to managing case teams supporting the preparation of complex and often interconnected expert reports, Ms. Wong consults to clients throughout the discovery process, as well as in mediation and preparation for deposition and trial.

View our promotions announcement

Analysis Group Congratulates Amol Navathe on Appointment as Chair of the Medicare Payment Advisory Commission

Fri, 05 Jun 2026 13:58:11 Z

Analysis Group congratulates Dr. Amol S Navathe on his appointment as chair of the Medicare Payment Advisory Commission (MedPAC). His three-year appointment was announced in May 2026.

Dr. Navathe is a health economist and a staff physician at Penn Presbyterian Medical Center. He specializes in the design and evaluation of health care payment and reimbursement models, health plan coverage, and medical service and prescription drug pricing, among other topics. Dr. Navathe’s research has been published in numerous peer-reviewed journals on topics such as machine learning and health care decision-making, improving the accuracy of risk adjustments, understanding the impact of value-based care and other payment models, and designing physician incentives to deliver high-value care.

MedPAC is an independent agency that provides the US Congress with analysis and policy advice on issues affecting the Medicare program.

Learn more about MedPAC

Analysis Group Authors Contribute to Policy Paper on Improving Early-Stage Cancer Care

Wed, 03 Jun 2026 20:33:16 Z

A central policy challenge in early-stage cancer care is how to evaluate and provide timely access to therapies while evidence is still evolving. Early detection and treatment can improve the likelihood of successful treatment and survival, underscoring the need for timely evidence on therapies in early-stage settings. In this context, early clinical endpoints – including event-free survival, disease-free survival, invasive disease-free survival, and recurrence-free survival – can provide earlier evidence on treatment effectiveness, which can then inform regulatory, reimbursement, and clinical decisions.

In the Journal of Medical Economics, Analysis Group Vice Presidents Debbie Goldschmidt and Jenny Zhou, together with academic affiliate Lou Garrison, of the Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute at the University of Washington School of Pharmacy, contributed to a policy paper that examines challenges in early-stage cancer diagnosis, treatment, and access. While early diagnosis and treatment can significantly improve patient outcomes, rates of early-stage detection continue to vary across tumor types and patient populations. The paper emphasizes that assessing treatment value in early-stage cancer can require considering a range of evidence, including early clinical endpoints that capture meaningful outcomes for patients such as whether treatment helps them remain disease-, event-, or recurrence-free.

Drawing on clinical and economic evidence, the authors explain that evidence-generation and value-assessment challenges in early-stage cancer care should not become a barrier to timely access. Instead, they highlight the importance of incorporating early clinical endpoints alongside other clinical, economic, and access considerations into evidence generation, value assessment, and reimbursement discussions, particularly when those measures reflect outcomes that matter to patients and can offer timely insights into whether innovative therapies reduce recurrence risk.

A key recommendation from the authors is the integration of early cancer care more fully into national cancer control plans, supported by stronger data collection and monitoring, improved health literacy, and more coordinated approaches to reimbursement and value assessment. Overall, they conclude that improving early-stage cancer care will require better alignment across stakeholders to enhance diagnosis rates, reduce the burden of recurrence, and expand timely access to effective treatments as evidence continues to evolve.

Read the article

Analysis Group Affiliate Ashish Jha Supports Defense Verdict in COVID-19 Vaccine Securities Class Action

Wed, 03 Jun 2026 14:35:31 Z

Analysis Group was retained on behalf of Armistice Capital, Armistice Capital Master Fund, and two Armistice executives, the defendants in a Rule 10b-5 securities fraud class action involving Vaxart, a clinical-stage biotech company developing oral recombinant vaccines. The plaintiffs alleged that Armistice orchestrated a stock manipulation and insider-trading scheme by causing Vaxart to issue false and misleading press releases regarding its COVID-19 vaccine candidate, including statements about Operation Warp Speed (OWS) and manufacturing capabilities. The plaintiffs claimed these statements artificially inflated Vaxart’s stock price, allowing Armistice to sell millions of shares at elevated prices before a subsequent decline.

An Analysis Group team led by Managing Principal Gaurav Jetley and Vice Presidents Michaela Johnson and Erica VanSant supported affiliate Ashish K. Jha, former White House COVID-19 Response Coordinator, who submitted an expert report and testified at trial. At trial, Dr. Jha testified on the known scope and criteria for OWS participation at the time of Vaxart’s statements. He testified that government stakeholders provided material support for vaccine development in a variety of ways under OWS.

A jury in the US District Court for the Northern District of California returned a defense verdict, finding for the defendants on all claims.

Affiliate Anthony Dukes and Analysis Group Coauthors Explore the Marketing Channel Differentiation Defense to Robinson-Patman Claims

Tue, 02 Jun 2026 18:52:42 Z

Price discrimination claims under the Robinson-Patman Act (RPA) have seen a resurgence in recent years, particularly in cases alleging that suppliers charged different prices for the same goods to competing downstream resellers, known as secondary-line claims. In parallel, firms are increasingly varying the promotion and pricing of their products across brick-and-mortar, e-commerce, and wholesale channels to accommodate the preferences and purchasing behavior of end customers. In some cases, resellers operating in different channels may not actually compete for the same customers, raising questions about when price discrimination results in injury to competition under the RPA.

Affiliate Anthony Dukes, Principal Laura O’Laughlin, Vice President Kristof Zetenyi, and Manager Brandon Norton explore the connection between marketing channel differentiation and liability under the RPA in an article published in Antitrust Report. The authors review recent secondary-line RPA cases and discuss the use of the “marketing channel differentiation” defense in such matters against the backdrop of established marketing theory. In addition to citing research on the prevalence and success of this defense, the authors consider how to assist factfinders’ determination of whether downstream retailers compete for the same end customers.

Read an excerpt from the article

IAM Recognizes Analysis Group Consultants as Leading Experts in Intellectual Property

Mon, 01 Jun 2026 17:19:57 Z

Fifteen Analysis Group consultants have been recognized as among the top economic experts for intellectual property (IP) matters in the IAM Patent 1000 – 2026. For this annual guide identifying outstanding patent professionals around the globe, Intellectual Asset Management (IAM) conducts extensive research, including interviews with attorneys and industry participants.

Based on this research, the guide recognized the following consultants for their exceptional expertise in patent matters: Managing Principals Rene Befurt, T. Christopher Borek, John C. Jarosz, Lauren R. Kindler, Jeffrey H. Kinrich, and Justin N. McLean; Principals Na Dawson, Robert L. Vigil, and Laura O’Laughlin; Vice Presidents John Browning, Mickey Ferri, and Thomas McGahee; Senior Advisors Carla S. Mulhern and Keith R. Ugone; and Independent Consultant Laura Boothman Stamm.

Regarding the firm, the guide notes that Analysis Group has “a deep bench of strong testifying experts, and the support teams to back them up. They can put out impressive amounts of work in short order as required by fast case schedules, while maintaining strong quality of work product.” The guide also highlights the consultants’ expertise across damages, valuation, and economic analysis in IP disputes.

2026 ASCO Annual Meeting

Fri, 29 May 2026 20:33:31 Z

Members of Analysis Group’s HEOR, Epidemiology & Market Access practice will present seven posters at the 2026 ASCO Annual Meeting. The program will feature a range of educational and scientific sessions on cancer research, treatment, and patient care.

Posters will be presented in Hall A of McCormick Place. Analysis Group poster presentations include:

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary – May 30, 2026, 9:00 a.m.–12:00 p.m. CT

“Real-world treatment patterns and overall survival (OS) in patients (pts) with HER2-positive (HER2+) advanced or metastatic gastroesophageal adenocarcinomas (mGEA) in the US,” coauthored by an Analysis Group team – including Managing Principal Keith Betts, Vice President Yan Wang, and Associates Shuang Wang and Ariel Chao – in collaboration with researchers from UC Irvine Health, Vanderbilt-Ingram Cancer Center, Dana-Farber Cancer Institute, Harvard Medical School, and Jazz Pharmaceuticals (sponsor).

Melanoma/Skin Cancers – May 31, 2026, 9:00 a.m.–12:00 p.m. CT

“Long-term efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma: An updated indirect treatment comparison (ITC) with 5-year follow-up data,” coauthored by an Analysis Group team – including Vice Presidents Viviana García-Horton and Jenny Zhou, Associate Hannah Kim, and Senior Analysts Dana Christensen and Matthew Mattera – in collaboration with researchers from The University of Texas MD Anderson Cancer Center, the University of Essen and the German Cancer Consortium, The Sidney Kimmel Comprehensive Cancer Center, Massachusetts General Hospital, Istituto Nazionale Tumori IRCCS Fondazione Pascale, The Royal Marsden NHS Foundation Trust, Aix-Marseille University, Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, and Bristol Myers Squibb (sponsor).

Hematologic Malignancies—Plasma Cell Dyscrasia – June 1, 2026, 9:00 a.m.–12:00 p.m. CT

“Comparative efficacy of linvoseltamab versus teclistamab in triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM): Updated matching-adjusted indirect comparison (MAIC) with longer follow-up,” coauthored by an Analysis Group team – including Vice Presidents Viviana García-Horton and Jenny Zhou, Manager Mirko Fillbrunn, and Senior Analysts Wenxin Ma and Matthew Mattera – in collaboration with researchers from the Sarah Cannon Research Institute, The Ohio State University Comprehensive Cancer Center, Icahn School of Medicine at Mount Sinai, Karmanos Cancer Institute, the University of Miami Health System, and Regeneron Pharmaceuticals (sponsor).

In addition, the following study has been accepted for online publication:

“Real-world use of piflufolastat F 18 and imaging-associated treatment patterns in early-stage prostate cancer,” coauthored by an Analysis Group team, including Managing Principal Noam Kirson, Manager Christopher Yee, Associate Emma Billmyer, and Senior Analyst Zhou Chen.

Is it Junk or is it Transparency?

Fri, 29 May 2026 14:33:14 Z

Managing Principal Rebecca Kirk Fair will moderate the American Bar Association Antitrust Law Section webinar Is it Junk or is it Transparency?. Presented by the Pricing Conduct Committee, the program will examine evolving US and Canadian policies on deceptive marketing, price transparency, class action trends, and related economic and competitive effects.

Panelists will include Hannah Johnson (McMillan LLP), Irene Cybulsky (Canadian Competition Bureau), Andrew Heimert (Federal Trade Commission, former), and Benjamin Nagin (Sidley Austin LLP).

17th Summit on Biosimilars & Innovator Biologics

Thu, 28 May 2026 19:41:53 Z

Vice President Andrea Hugill will join the panel Manufacturing Patents as the New Battleground: Protecting Biologics Manufacturing at the American Conference Institute’s 17th Summit on Biosimilars & Innovator Biologics. The panel will explore how companies are leveraging manufacturing patents and trade secrets to protect biologics manufacturing processes and preserve market exclusivity, and how courts are assessing infringement arguments based on process overlap, analytical characterization, and product-by-process claim frameworks.

Dr. Hugill will be joined by Maureen Bresnahan (Eisai), Jeffrey Jacobstein (Finnegan, Henderson, Farabow, Garrett & Dunner), Mary Morry (Merck Sharp & Dohme), and Matthew Murphy (Axinn, Veltrop & Harkrider).

Analysis Group is pleased to be an associate sponsor of this event.

Analysis Group Announces Three Senior-Level Promotions

Thu, 28 May 2026 13:51:33 Z

Analysis Group is pleased to announce the promotion of Rene Befurt and Joshua White to managing principal and Carletta Wong to principal.

New Managing Principals

New Principal

View our promotions announcement

Analysis Group Researchers Find Bariatric Surgery Rates Declining as GLP-1 Use Rises

Tue, 26 May 2026 17:23:02 Z

As the use of GLP-1 medications continues to rise in the US, their effect on rates of metabolic bariatric surgery (MBS) as a treatment for obesity and related cardiometabolic conditions remains an important question for patients, providers, and policymakers. Although prior research suggests that MBS utilization may be declining, examinations of national trends during the GLP-1 era have been limited to a period prior to the US Food and Drug Administration (FDA) approval of tirzepatide.

To quantify the association between GLP-1 use and rates of MBS, researchers, including Analysis Group Managing Principal Stephen Fink, Manager Robert J. Calzaretta, and affiliate Professor Thomas Tsai analyzed IQVIA PharMetrics® Plus with Mortality claims data from more than 11.7 million insured patients. In a research letter published in JAMA Surgery, the authors compare the quarterly rates of GLP-1 prescriptions and MBS utilization among patients with at least one obesity, overweight, or diabetes diagnosis from 2022 through 2024.

The authors find that GLP-1 use increased by more than 140% over the study period, while MBS utilization declined by 34%. Despite the rapid growth in GLP-1 medication use, they report that only about 9.5% of eligible patients received either a GLP-1 prescription or MBS, suggesting that obesity remains substantially undertreated. Their findings underscore the importance of monitoring evolving treatment patterns and ensuring patient access to both pharmacologic and surgical options for obesity care.

Read the study (paywall)

UK High Court Adopts FRAND Analysis of Analysis Group Academic Affiliate Justus Baron in Samsung v. ZTE

Tue, 26 May 2026 15:35:46 Z

Testimony from Analysis Group affiliate Justus Baron contributed to a trial win for Samsung Electronics in patent litigation brought against ZTE Corporation and related entities in the UK High Court of Justice. The case centered on a dispute over the terms of a global cross-license for the use of both parties’ standard essential patents (SEPs) for 4G and 5G mobile-phone technology following the expiration of a prior patent license agreement (PLA). While Samsung claimed that ZTE’s prior PLAs with Samsung and Apple should form the basis of the FRAND price, ZTE argued that Samsung’s license agreements with patent owners Ericsson, Nokia, and InterDigital (ENI), were a more appropriate benchmark.

Dr. Baron was retained on behalf of Samsung to evaluate the validity of a quantitative patent count comparison of the ZTE and ENI patent portfolios. He found that the ZTE portfolio, with many China-only and single-office patents, was not sufficiently comparable to the more established and geographically broad portfolios held by ENI.

Noting that “Dr Baron’s views were well-reasoned and carefully and precisely presented,” Mr. Justice Meade accepted Dr. Baron’s conclusion that “ZTE’s portfolio…cannot be reliably compared to portfolios of other SEP licensors such as Ericsson, Nokia, and InterDigital” and that “patents that belong to geographically broad patent families…are substantially more valuable.” Consistent with Samsung’s argument, the judge determined that ZTE’s prior PLAs should form the starting point for the new license terms.

Global Standards Leadership Conference

Thu, 21 May 2026 21:00:45 Z

Analysis Group Managing Principal John Jarosz will join a panel on patent disputes at the upcoming Global Standards Leadership Conference hosted by LexisNexis in San Diego. The conference will convene executives, thought leaders, and industry experts to discuss the future of licensing for standard essential patents (SEPs), FRAND determination, and litigation and policy trends. Mr. Jarosz will speak during a session titled “Global SEP Disputes and FRAND Frameworks,” which will explore evolving approaches to FRAND determination, global royalty setting, and preliminary injunctions across jurisdictions.

The EU Competition Law & AI Regulation Forum

Thu, 21 May 2026 14:51:02 Z

Managing Principal Lisa Pinheiro will join a panel at the EU Competition Law & AI Regulation Forum, hosted by ThoughtLeaders4 (TL4) Competition in Brussels. The forum will bring together legal, economic, and policy professionals to discuss evolving competition and regulatory issues related to AI.

Ms. Pinheiro will join the panel Analysing Data and How It Intersects with AI and Antitrust. It will examine access to data and data licensing, the impact of data on AI development, and AI agents and their use of data. The panel will be moderated by Konstantin Bondarenko (Freshfields), and panelists will include Marjolein De Backer (Eversheds Sutherland), Ashley Brickles (FTI Consulting), and Shula Teare van Hagan (DuckDuckGo).

Analysis Group is pleased to sponsor the event as a corporate partner of TL4.

The EU Competition Law & AI Regulation Forum

Thu, 21 May 2026 14:34:21 Z

Analysis Group is pleased to sponsor the event as a corporate partner of TL4.

15th Annual Conference of the American Society of Health Economists

Wed, 20 May 2026 20:49:37 Z

At the 15th Annual Conference of the American Society of Health Economists (ASHEcon), Maria Polyakova will receive the Kate Ho ASHEcon Medal, which is awarded to an early-career economist who has made significant contributions to the field of health economics. Professor Polyakova is an associate professor of Health Policy at Stanford School of Medicine and an associate professor (by courtesy) of Economics at Stanford University. Her research spans many areas of health economics, including health insurance, health care labor markets, and individual decision making in health and health care.

Analysis Group is proud to be a platinum-level sponsor of this event, as well as a sponsor of ASHEcon’s early-career mentoring session.

USC Gould / Analysis Group Global Competition Law Thought Leadership Conference

Mon, 18 May 2026 19:51:05 Z

Analysis Group Managing Principal Marissa Ginn will cohost a conference on antitrust and competition issues alongside D. Daniel Sokol (USC Gould School of Law and Marshall School of Business). FTC official Daniel Guarnera will deliver a keynote address, and leaders from prominent law firms, technology companies, and universities will join as panelists.

The conference will feature several Analysis Group consultants and affiliates in discussions on the following topics:

Vice President David Toniatti will join a panel discussing mergers.
Vice President David Smith will join a panel on algorithmic pricing and collusion.
Vice President Kristof Zetenyi will join a panel on the AI stack.
Manager Kritika Narula will moderate a panel on dominance.
Vice President George Derpanopoulos will join a panel on political antitrust.

2026 Antitrust in Health Care Conference

Mon, 18 May 2026 15:57:58 Z

Analysis Group Managing Principal Aditi Mehta will join a roundtable on economic analysis at the forefront of health care competition. The roundtable is part of the 2026 ABA Antitrust in Health Care Conference in Washington, DC. Dr. Mehta will be joined by Cory S. Capps (Bates White), Subramaniam Ramanarayanan (NERA), and Matt Schmitt (Econic Partners). The roundtable’s moderator is Sonia K. Pfaffenroth (Arnold & Porter Kay Scholer).

Analysis Group Collaborates in Prospective Multicenter Study on the Role of Screening Strategies for Advancing Early Detection of Pulmonary Hypertension in Patients with Interstitial Lung Disease

Thu, 14 May 2026 18:17:02 Z

Pulmonary hypertension (PH) is a common complication of interstitial lung disease (ILD) that is associated with diminished quality of life and decreased survival. The US Food and Drug Administration (FDA) has approved a therapy to improve exercise capacity among patients with ILD-associated PH. However, standardized screening for PH in patients with ILD is lacking, which can lead to delays in diagnosis and treatment.

To identify appropriate parameters for the detection of PH in those patients, researchers including Managing Principal Maral DerSarkissian collaborated on the Pulmonary Hypertension Screening in Patients with Interstitial Lung Disease for Earlier Detection (PHINDER) study. PHINDER is a multicenter, non-interventional prospective study of clinical, functional, imaging, and echocardiographic information collected from pre-specified assessments that were incorporated into clinical workflows within participating health care centers. The research required complex coordination across multiple centers and health care providers to support patient recruitment and enrollment, integration of assessments into routine care, and prospective data collection from approximately 200 patients, with a target enrollment of up to 300 patients. The study identified potential predictors of PH using data from patients with ILD who underwent the pre-specified assessments and right heart catheterization.

In an article describing their work, the researchers present preliminary evidence that combining pulmonary function testing, lung imaging, and echocardiography could improve earlier and more accurate detection of PH among patients with ILD. They conclude that their preliminary findings support the integration of imaging tests and functional assessments in PH diagnostic screening protocols for patients with ILD. Final analyses are underway.

The article, “Screening for Pulmonary Hypertension in Interstitial Lung Disease: Preliminary Results from the PHINDER Study,” was published in Advances in Therapy. Funding for the study was provided by United Therapeutics.

Read the article

Analysis Group Launches Experts’ Table Series with a Discussion on AI and Competition in Europe

Thu, 14 May 2026 14:32:35 Z

Analysis Group Managing Principal Joshua White, Principal Chris Feige, and Vice President Cyril Hariton hosted the first in Analysis Group’s Experts’ Table discussion series in Brussels, convening a small group of legal practitioners to discuss AI at the intersection of economics, law, regulation, and policy. The conversation featured academic affiliate Timothy DeStefano, an applied economist whose work focuses on digital technology, AI, industrial robotics, firm productivity, and trade.

The discussion explored whether AI markets are naturally prone to concentration, given the importance of costly inputs such as cloud infrastructure, computing resources, advanced models, and proprietary data. Participants considered whether scale advantages and first-mover positions may favor a small number of firms, or whether factors such as hardware innovation, specialized models, open-source tools, and tailored use cases could help keep the market competitive.

The group also discussed the challenges of AI diffusion across firms and the implications for Europe’s competitiveness. Participants noted that adoption is not simply a question of access to frontier technology: Firms also face organizational, skill, infrastructure, and investment barriers. The group considered whether Europe should broaden its focus beyond innovation and digital sovereignty to diffusion-enabling conditions such as cloud adoption, data interoperability, and digital infrastructure.

The Experts’ Table series forms part of Analysis Group’s ongoing commitment to convening focused, high-level conversations on emerging issues affecting clients across Europe and globally.

Analysis Group Launches Experts’ Table Series with a Discussion on AI and Competition in Europe

Thu, 14 May 2026 14:27:22 Z

The Experts’ Table series forms part of Analysis Group’s ongoing commitment to convening focused, high-level conversations on emerging issues affecting clients across Europe and globally.

GAR Live: ISDS

Wed, 13 May 2026 14:01:53 Z

During London International Disputes Week in June, Analysis Group Principal Jessica Resch will join a panel on quantum evidence at GAR Live. The session will explore how the current climate of geopolitical uncertainty complicates quantum assessments. Panelists will discuss innovative approaches to quantum, the application of AI tools, and how to work effectively with quantum experts.

GAR Live: ISDS

Wed, 13 May 2026 13:59:16 Z

GCR Live: Europe

Tue, 12 May 2026 14:10:25 Z

Analysis Group Managing Principal Aditi Mehta and Competition Expert Pierre Régibeau will discuss antitrust enforcement at the upcoming GCR Live: Europe in Brussels. The conference will convene private practitioners, corporate counsel, and government enforcers to explore key developments in competition law. Dr. Régibeau will join a panel on the future of EU antitrust enforcement, exploring recent cases, cartel enforcement, and the role of economists. Dr. Mehta will speak on a panel on US enforcement developments.

Analysis Group is pleased to be the sole Platinum Sponsor of this event.

GCR Live: Europe

Tue, 12 May 2026 14:04:13 Z

Analysis Group is pleased to be the sole Platinum Sponsor of this event.

60th Annual Meetings of the Canadian Economics Association (CEA 2026)

Mon, 11 May 2026 17:37:50 Z

Vice President Nick Dadson will chair a session on data science and economics at the Canadian Economics Association Annual Conference.

Analysis Group is pleased to support this year’s conference as a sponsor of the Embrace Day Graduate Student Mentoring Session, Friday Night Cocktail Reception, and State of the Art Lecture.

Dispute Resolution in M&A Transactions International Conference

Mon, 04 May 2026 14:38:24 Z

Analysis Group Principal Jessica Resch will present on a panel of economic experts at the Dispute Resolution in M&A Transactions International Conference in Warsaw. The session, which will be moderated by ICC Poland President Dr hab. Beata Gessel-Kalinowska vel Kalisz, will explore asset-based and cash-based valuations and the future of damages, both in the context of non-going concerns and in light of UNCITRAL Working Group III proposed investor-state dispute settlement reforms.

Dispute Resolution in M&A Transactions International Conference

Mon, 04 May 2026 14:32:54 Z

2026 Whoop It Up for Women Comedy Night

Fri, 01 May 2026 14:43:01 Z

Analysis Group is proud to sponsor the Whoop It Up for Women Comedy Night for the third year in a row. The evening is the signature fundraiser for the WBF, whose mission is to ensure access to justice for low-income people. This includes providing pro bono legal assistance through WBF initiatives such as the Family Law Project for Survivors of Domestic Abuse, the Elder Law Project, the Women’s Prison & Re-Entry Project, and the Clemency Project.

Elizabeth Mooney, associate general counsel at Analysis Group, is vice president of WBF’s board of trustees, as well as co-chair of the Nominations and Governance Committee, and a member of the Amicus Committee.

CBA Economics Roundtable 2026: Negotiation and Market Power in Antitrust Enforcement

Wed, 29 Apr 2026 19:55:21 Z

Analysis Group Vice President Shannon Seitz will join a panel at the Canadian Bar Association (CBA) Economics Roundtable 2026: Negotiation and Market Power in Antitrust Enforcement.

She will participate in Antitrust Enforcement in Labour Markets, a session focused on enforcement strategies for addressing monopsony power and collective bargaining frictions, and the role of economic tools in supporting legal analysis in labor market cases. Panelists include Ioana Marinescu (University of Pennsylvania) and Bill Wu (McMillan LLP). Matthew Strathearn (Competition Bureau) will moderate the session.

The Roundtable will examine how economic models of bargaining are applied in antitrust enforcement, with implications for merger review, conduct investigations, and labor market cases.

Assessment of Cartel Overcharges by European Courts

Tue, 28 Apr 2026 18:14:15 Z

Analysis Group Vice President Philipp Tillmann will join an American Bar Association webinar with Katharina Kolb (Lieff Cabraser Heimann & Bernstein) on European courts’ assessments of cartel overcharges, particularly in light of recent developments in Germany and the Netherlands.

Assessment of Cartel Overcharges by European Courts

Tue, 28 Apr 2026 18:11:59 Z

ISPOR 2026

Tue, 28 Apr 2026 14:22:10 Z

Analysis Group, a global leader in health economics and outcomes research (HEOR), epidemiology, and market access, will present an educational symposium, join two panel discussions, contribute to a podium presentation, and share 25 research posters at ISPOR 2026, which will be held at the Pennsylvania Convention Center in Philadelphia, PA.

Managing Principal Eric Wu, Principal Jimmy Royer, and Professor Liming Liang (Harvard T.H. Chan School of Public Health) will present an educational symposium titled “Driving the Next Era of Evidence-Based Medicine through AI, Diverse Data, and Collaboration.” The symposium will explore how cutting-edge GenAI methodology can be applied to develop comprehensive and up-to-date insights on diseases and treatment outcomes from heterogeneous data sources. Presenters will showcase the application of GenAI with digital twin methodologies to simulate the long-term progression of obesity and chronic cardiometabolic diseases.

The symposium will also introduce a new real-world evidence research initiative jointly launched by the Harvard T.H. Chan School of Public Health and Analysis Group, focused on advancing precision health through the application of AI to better understand disease pathways, treatment effectiveness, and personalized health. The symposium will be held on Tuesday, May 19, at 12:15 p.m.

Additional presentations:

Managing Principal Min Yang will participate as a panelist in the forum titled “HEOR Skills Building: Essential Skills for the Future” on Monday, May 18, at 12:15 p.m.
Principal Jimmy Royer will participate as a panelist in the forum titled “The Enduring Challenge of Medical Device Identification in Real-World Data: Is Artificial Intelligence Abstraction Ready for Broad Use and Acceptance?” on Monday, May 18, at 12:15 p.m.
A study coauthored by Vice President Weiguang Xue, Manager Yanwen Xie, and Senior Analyst Jack Eales titled “Consideration of Indirect Effects in National Vaccine Evaluations and Recommendations: A Scoping Review” will be shared as a podium presentation on Monday, May 18, at 1:45 p.m.

Further details on these presentations and Analysis Group’s posters are available in our ISPOR 2026 Presentation Guide.

ISPOR 2026

Tue, 28 Apr 2026 14:13:26 Z

Additional presentations:

Managing Principal Min Yang will participate as a panelist in the forum titled “HEOR Skills Building: Essential Skills for the Future” on Monday, May 18, at 12:15 p.m.
Principal Jimmy Royer will participate as a panelist in the forum titled “The Enduring Challenge of Medical Device Identification in Real-World Data: Is Artificial Intelligence Abstraction Ready for Broad Use and Acceptance?” on Monday, May 18, at 12:15 p.m.
A study coauthored by Vice President Weiguang Xue, Manager Yanwen Xie, and Senior Analyst Jack Eales titled “Consideration of Indirect Effects in National Vaccine Evaluations and Recommendations: A Scoping Review” will be shared as a podium presentation on Monday, May 18, at 1:45 p.m.

Further details on these presentations and Analysis Group’s posters are available in our ISPOR 2026 Presentation Guide.

CBA Competition Law Spring Conference

Thu, 23 Apr 2026 19:04:15 Z

Principal Laura O’Laughlin will speak at the 2026 CBA Competition Law Spring Conference, delivering both opening and closing remarks. She is a co-chair of the conference along with Joshua Chad (McMillan). Analysis Group is a sponsor of the conference.

Held under the theme “Shifting Terrain: Navigating Canada’s Competition and Investment Law Landscape,” the conference will examine key developments in Canada’s competition and foreign investment regimes. Sessions will explore the implications of AI for competition policy, the intersection of the Building Canada Act with investment review, evolving approaches to private enforcement and consumer protection litigation, and recent changes to merger enforcement. The conference will bring together legal practitioners, policymakers, and industry leaders to discuss emerging challenges and practical strategies in a rapidly evolving regulatory environment.

Revisiting the Attempted Kroger-Albertsons Merger

Fri, 10 Apr 2026 19:12:12 Z

Analysis Group Vice President Liz Milsark will join a webinar panel on the attempted Kroger-Albertsons Merger, hosted by the CBA Economics and Law Committee jointly with the CBA Young Lawyers Committee of the CBA Competition Law and Foreign Investment Review Section. The panel will examine the termination of the proposed Kroger-Albertsons merger following rulings in the US District Court for the District of Oregon and the King County Superior Court for the State of Washington and will explore key thoughts and takeaways related to the antitrust outlook and its applications to Canadian law.

Panelists include Emily Blackburn (King & Spalding) and Kuruvilla J. Olasa (Munger, Tolles & Olson). Nadia Soboleva (Charles River Associates) will moderate the panel.

International Industrial Organization Conference (IIOC)

Wed, 01 Apr 2026 16:59:38 Z

Two Analysis Group consultants will participate in the 24th Annual International Industrial Organization Conference.

Managing Principal Aditi Mehta (former head of the Economic Analysis Group at the US Department of Justice Antitrust Division) will introduce the Merger Remedies session.
Vice President Riccardo Marchingiglio will be a panel discussant on Doing IO at Antitrust Consulting Firms.

Analysis Group is pleased to be a sponsor of this event.

ABA Antitrust Law Spring Meeting

Fri, 13 Mar 2026 10:41:32 Z

Consultant and affiliates from Analysis Group’s Antitrust & Competition practice will join panels at the 2026 ABA Antitrust Law Spring Meeting in Washington, DC.

Manager Stephanie D. Cheng will join the Fundamentals – Economics panel, which will cover core economic principles in antitrust cases, including damages and econometrics. The panel will be moderated by Sergei Zaslavsky (O’Melveny & Myers LLP), and panelists will include Craig R. Malam (Edgeworth Economics), Jeremy Sandford (Econic Partners LLP), and Emily N. Walden (NERA Economic Consulting).
Affiliate On Amir (Rady School of Management at UC San Diego) will join All-Inclusive? The Risky World of Pricing, a session examining regulatory and litigation trends related to pricing practices, consumer perception, and subscription models. The panel will be moderated by William C. MacLeod (Kelley Drye & Warren LLP), and panelists will include Emily Chissell (Keystone Strategy), Matthew Michaloski (Utah Office of the Attorney General), and John Roberti (Zaiger Linden Roberti & Pepe LLC).
Affiliate Keith N. Hylton (Boston University School of Law) will participate in Evidently, We Need More—Burden’s On You!, a panel addressing evolving evidentiary standards for private antitrust plaintiffs across jurisdictions. The panel will be moderated by Heather T. Rankie (Zelle LLP), and panelists will include Euan Burrows (White & Case LLP), Jennifer Reeves (Geradin Partners), and Nana Wilberforce (WilmerHale).

9th Annual USD School of Law Transfer Pricing Innovation Symposium

Thu, 12 Mar 2026 17:22:10 Z

Analysis Group consultants will present on a panel at the 9th Annual University of San Diego School of Law Transfer Pricing Innovation Symposium, where professionals in global tax, finance, accounting, and law will engage with experts on legal and economic trends impacting transfer pricing compliance, planning, and disputes.

Managing Principal Alan White, Vice President Steve Allen, and Kevin Kiyan (Andersen) will evaluate two transfer pricing methodologies – comparable uncontrolled transaction (CUT) and the comparable profit method (CPM) – in the session “CUT vs CPM – Would the Best Method please stand up!!”

ASCO Genitourinary Cancers Symposium

Mon, 09 Mar 2026 19:57:05 Z

Researchers from Analysis Group’s HEOR, Epidemiology & Market Access practice will present six posters at the American Society of Clinical Oncology’s (ASCO’s) annual Genitourinary Cancers Symposium, which will be held February 26–28, 2026, in San Francisco, CA.

The firm’s poster presentations will include:

Poster Session A: Prostate Cancer – February 26

Abstract 338: “Patient (pt) preferences for treatment (tx) of non-metastatic hormone-sensitive prostate cancer (nmHSPC): A discrete choice experiment (DCE)” coauthored by an Analysis Group team – including Managing Principal Hongbo Yang, Vice President Weiguang Xue, and Manager Yan Meng – in collaboration with researchers from START Carolinas/Carolina Urologic Research Center, University Hospital Schleswig-Holstein, and Astellas Pharma.

This study was sponsored by Astellas Pharma.

Abstract 106: “Real-world comparison of prostate-specific antigen (PSA) response in metastatic castration-sensitive prostate cancer (mCSPC) patients treated with apalutamide (APA) without docetaxel vs darolutamide (DARO) without docetaxel,” coauthored by an Analysis Group team – including Vice President Dominic Pilon, Manager Carmine Rossi, Associate Frederic Kinkead, and Senior Research Professionals Alessio Palladino and Gordon Wong – in collaboration with researchers from Chesapeake Urology, New Jersey Urology, the Winship Cancer Institute of Emory University, and Johnson & Johnson.

This study was sponsored by Johnson & Johnson.

Abstract 343: “Real-world clinical outcomes among patients with localized prostate cancer (LPC) undergoing radical prostatectomy (RP),” coauthored by an Analysis Group team – including Vice President Dominic Pilon, Manager Carmine Rossi, Associate Frederic Kinkead, and Senior Research Professionals Francesca Lee, Yuxi Wang, and Gordon Wong – in collaboration with researchers from Advent Health Urology, Chesapeake Urology, New Jersey Urology, START Carolinas/Carolina Urologic Research Center, and Johnson & Johnson.

This study was sponsored by Johnson & Johnson.

Abstract 180: “Real-world (RW) outcomes associated with enzalutamide (enza) vs apalutamide (apa) in metastatic castration sensitive prostate cancer (mCSPC): Analysis of United States (US) oncology electronic health record (EHR) data,” coauthored by an Analysis Group team – including Managing Principals Maral DerSarkissian and Mei Sheng Duh, Vice President Priyanka Bobbili, and Associate Naiyu Chen – in collaboration with researchers from the Dana-Farber Cancer Institute, Astellas Pharma, and Pfizer.

This study was sponsored by Astellas Pharma and Pfizer.

Poster Session B: Prostate Cancer and Urothelial Carcinoma – February 27

Abstract 709: “Quality of care (QoC) measures among patients with recurrent, papillary-only Bacillus Calmette-Guérin (BCG)-experienced high-risk non-muscle invasive bladder cancer (HR-NMIBC),” coauthored by an Analysis Group team – including Vice Presidents Bruno Émond and Dominic Pilon, Managers Rebecca Bungay and Carmine Rossi, and Senior Analyst Steven Liu – in collaboration with researchers from the Stanford University School of Medicine, Medstar Georgetown University Hospital, and Johnson & Johnson.

This study was sponsored by Johnson & Johnson.

Abstract 708: “Front-line (1L) treatment and recurrence patterns among patients with high-risk non–muscle-invasive bladder cancer (HR-NMIBC) with papillary carcinoma (PAP) or carcinoma in situ (CIS) following Bacillus Calmette-Guérin (BCG) or other intravesical therapies (IVT),” coauthored by an Analysis Group team – including Vice Presidents Bruno Émond and Dominic Pilon, Managers Rebecca Bungay and Carmine Rossi, and Senior Analyst Steven Liu – in collaboration with researchers from the Stanford University School of Medicine, Medstar Georgetown University Hospital, and Johnson & Johnson.

This study was sponsored by Johnson & Johnson.

Generative AI for Disease Modeling

Mon, 09 Mar 2026 18:09:24 Z

Principal Jimmy Royer, Director of Data Science Max Leroux, and Senior Data Scientist Intekhab Hossain will lead an American Statistical Association webinar on generative AI (GenAI) and its use in disease modeling. The webinar will highlight Analysis Group’s Dynamic Evaluation of Cardiometabolic Obesity Disease (DECODE) GenAI model, a digital twin that can simulate long-term benefits of weight loss on cardiometabolic conditions. Webinar attendees will learn how DECODE uses longitudinal data to model obesity progression, and how GenAI models can inform health economics and outcomes research and policy decisions.

Antitrust Updates – Damages, Big Data and FTC Trends

Fri, 06 Mar 2026 17:56:04 Z

At a conference hosted by the State Bar of Georgia’s Antitrust Law Section, Principal Juliette Caminade will discuss evolving trends in injury and damages analysis in the era of two-sided platforms and monopolization cases. The discussion is part of the broader conference program titled Antitrust Updates – Damages, Big Data and FTC Trends.

The conversation will be moderated by David Schwartz (Bryan Cave Leighton Paisner) and will also feature Rosa M. Abrantes-Metz (BRG).

2026 Intellectual Property Institute

Thu, 05 Mar 2026 15:56:05 Z

Analysis Group Managing Principal Jeff Kinrich will join the panel “Calculating Victory: In-House Strategies and Recent Updates for Patent Damages” at USC’s 2026 Intellectual Property Institute in Santa Monica.

The session will bring together in-house counsel, outside counsel, and damages experts to discuss the evolving role of in-house legal teams in shaping patent damages strategies. Panelists will examine strategic decisions typically addressed by outside counsel and experts, provide updates on recent pivotal cases – including Rex Medical v. Intuitive Surgical and EcoFactor, Inc. v. Google LLC – and explore current trends in apportionment and licensing comparability that influence damages claims.

ASCO Genitourinary Cancers Symposium

Wed, 25 Feb 2026 15:31:37 Z

The firm’s poster presentations will include:

Poster Session A: Prostate Cancer – February 26

Abstract 338: “Patient (pt) preferences for treatment (tx) of non-metastatic hormone-sensitive prostate cancer (nmHSPC): A discrete choice experiment (DCE),” coauthored by an Analysis Group team – including Managing Principal Hongbo Yang, Vice President Weiguang Xue, and Manager Yan Meng – in collaboration with researchers from START Carolinas/Carolina Urologic Research Center, University Hospital Schleswig-Holstein, and Astellas Pharma.

This study was sponsored by Astellas Pharma.

Abstract 106: “Real-world comparison of prostate-specific antigen (PSA) response in metastatic castration-sensitive prostate cancer (mCSPC) patients treated with apalutamide (APA) without docetaxel vs darolutamide (DARO) without docetaxel,” coauthored by an Analysis Group team – including Vice President Dominic Pilon, Manager Carmine Rossi, Associate Frederic Kinkead, and Senior Research Professionals Alessio Palladino and Gordon Wong – in collaboration with researchers from Chesapeake Urology, New Jersey Urology, the Winship Cancer Institute of Emory University, and Johnson & Johnson.

This study was sponsored by Johnson & Johnson.

Abstract 343: “Real-world clinical outcomes among patients with localized prostate cancer (LPC) undergoing radical prostatectomy (RP),” coauthored by an Analysis Group team – including Vice President Dominic Pilon, Manager Carmine Rossi, Associate Frederic Kinkead, and Senior Research Professionals Francesca Lee, Yuxi Wang, and Gordon Wong – in collaboration with researchers from Advent Health Urology, Chesapeake Urology, New Jersey Urology, START Carolinas/Carolina Urologic Research Center, and Johnson & Johnson.

This study was sponsored by Johnson & Johnson.

Abstract 180: “Real-world (RW) outcomes associated with enzalutamide (enza) vs apalutamide (apa) in metastatic castration sensitive prostate cancer (mCSPC): Analysis of United States (US) oncology electronic health record (EHR) data,” coauthored by an Analysis Group team – including Managing Principals Maral DerSarkissian and Mei Sheng Duh, Vice President Priyanka Bobbili, and Associate Naiyu Chen – in collaboration with researchers from the Dana-Farber Cancer Institute, Astellas Pharma, and Pfizer.

This study was sponsored by Astellas Pharma and Pfizer.

Poster Session B: Prostate Cancer and Urothelial Carcinoma – February 27

Abstract 709: “Quality of care (QoC) measures among patients with recurrent, papillary-only Bacillus Calmette-Guérin (BCG)-experienced high-risk non-muscle invasive bladder cancer (HR-NMIBC),” coauthored by an Analysis Group team – including Vice Presidents Bruno Émond and Dominic Pilon, Managers Rebecca Bungay and Carmine Rossi, and Senior Analyst Steven Liu – in collaboration with researchers from the Stanford University School of Medicine, Medstar Georgetown University Hospital, and Johnson & Johnson.

This study was sponsored by Johnson & Johnson.

Abstract 708: “Front-line (1L) treatment and recurrence patterns among patients with high-risk non–muscle-invasive bladder cancer (HR-NMIBC) with papillary carcinoma (PAP) or carcinoma in situ (CIS) following Bacillus Calmette-Guérin (BCG) or other intravesical therapies (IVT),” coauthored by an Analysis Group team – including Vice Presidents Bruno Émond and Dominic Pilon, Managers Rebecca Bungay and Carmine Rossi, and Senior Analyst Steven Liu – in collaboration with researchers from the Stanford University School of Medicine, Medstar Georgetown University Hospital, and Johnson & Johnson.

This study was sponsored by Johnson & Johnson.

MIT Sloan Healthcare and Bioinnovations Conference

Fri, 20 Feb 2026 19:02:24 Z

At the MIT Sloan Healthcare and Bioinnovations Conference, Analysis Group Vice President Priyanka Bobbili will moderate the “Next Frontier of Cardiovascular Innovation” panel, which will explore emerging breakthroughs in cardiovascular therapeutics and management, spanning pharmaceutical, medical device, and digital health innovation. Panelists will examine how advances across these areas intersect with challenges related to access, integration, and care delivery across the full patient journey.

Panelists will include Elazer Edelman (Massachusetts Institute of Technology; Harvard Medical School; Brigham and Women’s Hospital), Glen Fantuzzi (Johnson & Johnson), Cecilie Heerdegen Jepsen (Novo Nordisk), and Shyamal Patel (Oura).

Analysis Group is a proud sponsor of this event.

Revisiting Airline Antitrust

Tue, 17 Feb 2026 17:24:16 Z

Managing Principal Maria E. Garibotti will moderate the American Bar Association Antitrust Law Section’s Revisiting Airline Antitrust webinar. The program will examine recent developments in airline competition policy, including the US Department of Justice and US Department of Transportation’s withdrawal of support for antitrust immunity for the Delta Air Lines–Aeromexico joint venture, the injunction against the American Airlines–JetBlue Northeast Alliance, the abandoned JetBlue–Spirit merger, and the agencies’ call for comments on the state of competition in the airline industry.

Panelists include Daniel Culley (Cleary Gottlieb), Ed Duffy (Baker Botts), and Jeffrey Prince (Indiana University). Together, they will explore what distinguishes airline antitrust enforcement and consider the implications of recent agency actions for joint ventures and industry structure.

BYU Law Winter Deals Conference

Tue, 27 Jan 2026 19:35:29 Z

At BYU Law’s 2026 Winter Deals Conference, Managing Principal Lauren Hunt will join a panel commenting on the paper “Private Equity, Public Capital, and Litigation Risk” by Ludovic Phalippou (Saïd Business School, University of Oxford) and Wiliam J. Magnuson (Texas A&M University School of Law). Analysis Group is pleased to be a sponsor of this event.

New Frontiers of Antitrust Conference

Fri, 22 Aug 2025 16:00:50 Z

Managing Principal Antoine Chapsal will join a panel examining recent developments in merger control and foreign investment regulation across Europe at Concurrences’ New Frontiers of Antitrust conference. The discussion will cover structural versus behavioral remedies, first-mover advantage as a source of anticompetitive risk, the EU’s Foreign Subsidies Regulation and foreign direct investment regime, and the UK’s National Security and Investment Act. Panelists will include Aude-Laure Delbac (European Commission), Thomas Ernoult (DG Trésor), Karima El Sammaa (ArcelorMittal), Damien Levie (DG Trade), Séverine Schrameck (Cleary Gottlieb), and moderator Francesco Martucci (Panthéon-Assas University).

New Frontiers of Antitrust Conference

Wed, 20 Aug 2025 13:12:06 Z